

生物科技誌

BIOTECHGAZINE

DEC 2022

BIOHK2022

香港國際生物科技展

Convention Summary

DATE

DEC 14 - DEC 17, 2022

LOCATION

**HONG KONG CONVENTION AND
EXHIBITION CENTRE HALL 5/FG**



Scan To
Subscribe



BIOTECHGAZINE

BIOHK2022
主辦單位:



BayHelix
G R O U P

AUSVIC
Capital

About BIOHK2022

Convention Theme

To create a global platform in which there are infinite possibilities and zero limitations on what you can accomplish in biotechnology.

What is BIOHK2022?

An international convention organized by Hong Kong Biotechnology Organisation to introduce novel state-of-the-art biotech innovations from around the globe, with the purpose of providing an extensive platform to allow pioneers of the biotech industry to convene. From infectious diseases like COVID-19, to the latest cancer treatments and diagnostics to big data analytics, BIOHK2022 is an unparalleled event covering the most relevant and timely topics in biotechnology. BIOHK2022 comprises of three parts:

Exhibition - SHOWCASE and CONNECT

- Showcase your product to the world whilst simultaneously learning about other leading innovations

Conference and Pitch Sessions - SHARE AND INSPIRE

- Take part in invaluable discussions about the latest topics and industry trends in biotech

One2One Partnering - PROMOTE AND ESTABLISH

- Promote your company and connect with prospective partners in the biotech market, succeed in forming new collaborations and building your international network

The last part of the convention would open for the public. Visitors could participate in public talks. It would be the best chance to promote your brand and company! Let the public know about your newest product and valuable ideas!

Dec 2022

編輯委員會 Editorial Committee

總編輯 Chief Editor

于常海教授 PhD, JP

Prof. Albert Cheung-Hoi YU, PhD, JP

副總編輯 Deputy Chief Editor

陳一謬

Ayo Yi-Ngok CHAN

委員 Committee Members

(按筆畫數排列 Arranged according to stroke count)

江宜業教授 MD

Gina JIANG, MD

李小羿教授 PhD

Prof. Benjamin Xiao-Yi LI, PhD

周志偉教授 PhD

Prof. Wilton Chi-Wai CHAU, PhD

陳偉傑

Danny Wei-Jie CHEN

黃達東 MH, JP

Tat-Tung Dennis WONG, MH, JP

盧毓琳教授 BBS

Prof. Yuk-Lam LO, BBS

李天立教授 PhD

Prof. Tin-Lap LEE, PhD

梁潤松教授 PhD

Prof. Thomas Yun-Chung LEUNG

黃炳鏐 PhD

Bing-Lou WONG, PhD

劉安庭

Andy An-Ting LIU

蕭文鸞教授 PhD

Prof. Wendy Wen-Luan HSIAO, PhD

出版社 Publisher

海康生命出版社有限公司 H.K. Life Publishing Limited

電話 Tel: (852) 2111 2123

傳真 Fax: (852) 2111 9762

電郵 Email: editorial@biotechgazine.com

廣告查詢 Advertising

電郵 Email: info@biotechgazine.com

出版日期 Publishing Date

2022年12月 December 2022

定價 Price

HK\$40

ISBN

978-988-76503-4-8

版權所有，未經本會及作者同意，不得翻印

All reproduction requests are subject to the approval of HKBIO and authors



Table of Content

About Convention

Convention Data	P.4 - 5
Welcome message from Presidents	P.15 - 16
Structure of Organising communittee	P.17 - 23
Program Informations	P.24
Exhibitor List	P.25 - 26
Sessions' Introduction	P.27
Day 1 Schedule	P.28 - 32
Day 2 Schedule	P.33 - 43
Day 3 Schedule	P.44 - 50
Day 4 Schedule	P.51 - 55
Supporting Organizations	P.123 - 125
Acknowledgment List	P.126

Company Introduction

Deloitte China	P.6 - 7
DBS Bank (Hong Kong) Limited	P.8 - 9
Lee's Pharmaceutical (HK) Limited	P.10
Zhaoke (Hong Kong) Ophthalmology Pharmaceutial Limited	P.11
Koln 3D Technology (Medical) Limited	P.12 - 13
Hai Kang Life Corporation Limited	P.14
GenScript Biotech	P.56 - 57
Tiger Jade Capital, LLP	P.58
Sirnaomics Limited	P.59
Invest Hong Kong	P.60
Hong Kong Cyberport Management Company Limited	P.61
China Biotech Services Holding Limited	P.62
Asian Fund For Cancer Research Limited	P.63
Nano and Advanced Materials Institute Limited	P.64
City University of Hong Kong	P.65
Gracell Biotechnologies	P.66
U.S. Pacific Nonwovens Industry Limited	P.67
Certizen Technology Limited	P.68
Eversana Hong Kong Limited	P.69
Sunrise Diagnostic Centre Limited	P.70

DreamTec Limited	P.71	HKG Epitherapeutics Limited	P.97
Green Life Technology Limited	P.72	BGI Health (HK) Company Limited	P.98
Hong Kong University of Science and Technology (OKT)	P.73	College of American Pathologists	P.99
eNano Health Limited	P.74	Agilent Technologies Hong Kong Limited	P.100 - 101
Hong Kong Center for Clinical Research	P.75	Immune Materials Limited	P.102
Max Choice Corporation Limited	P.76	Tronex (Hong Kong) Limited	P.103
SinoVeda Canada Inc.	P.77	Sense Time Group Limited	P.104
Health Advances Asia Limited	P.78	OrbusNeich Medical Company Limited	P.105
Immune Materials Limited	P.79	Gallant Biotechnology Limited	P.106
HK-Dtech Limited	P.80	Catagene Limited (CMA)	P.107
Agilis Robotics	P.81	AlphaHygienic Co. Limited	P.108
Eagle IP Limited	P.82	H&W Group (Greater China) Limited	P.109
Insilico Medicine Hong Kong Limited	P.83	Centre for Novostics Limited	P.110
Crystal Peace Health Science Limited	P.84	The Commercial Press (HK) Limited	P.111
InCompass IP Limited	P.85	D&D Electronics Co., Limited	P.112
Bioprobes Limited	P.86	GenieBiome Limited	P.113
Hong Kong New Generation Cultural Association	P.87	Clinixir Company Limited	P.114
AlpaLife (Shenzhen KangTi Life Technology Co., Limited)	P.88	AP Infosense Limited	P.115
Sanwa BioTech Limited	P.89	Hong Kong Institute of Biotechnology Limited	P.116
Midland Financial Group	P.90	MGI International Sales Co.Limited	P.117
Intellectual Property Department, the Government of the HKSAR	P.91	A Plus Healthcare Development Limited	P.118
BETH Bioinformatics Co. Limited	P.92	Gense Technologies Limited	P.119
ZSHK Laboratories Limited	P.93	Hong Kong University of Science and Technology	P.120
HK Council for Testing and Certification	P.94	Phase Scientific International Limited	P.121
Jiangsu Cowin Biotech Co., Limited	P.95	DNA-Tech Limited	P.122
Taoist Culture of Healthy Living Association Limited	P.96		

In BIOHK2022 Convention

6916

Visitors in person

140

Standard booths

740K+

Online Visitors

160

Speakers

8

Plenary Sessions

3

Workshops

12

Forums

7

Symposiums

8

Roundtables

Deloitte.

德勤



INspire HK 躍動香港

INnovate and unite for a vibrant future

At Deloitte, we always strive for excellence in everything we do.

INspire HK pledges HKD1 billion over the next three years to double down on the growth of our Hong Kong practice by advancing our firm's multidisciplinary services model (MDM), enhancing talent development, and strengthening our position as an integrated, full-service professional services firm.

Harnessing our innovative MDM, we will deliver greater value and impact for our clients through five integrated value propositions (IVPs):

E2E M&A | E2E Sustainability | E2E Digital | ONEInsurance | Smart City

Empowering transformation for a brighter future

This year, Deloitte celebrates its 50th Anniversary in Hong Kong, paying tribute to our clients, people, and community - and the iconic skyline that symbolises HKSAR's enduring energy and dynamism.



www.deloitte.com/cn

35/F One Pacific Place, 88 Queensway, Hong Kong
Tel: +852 2852 1600 Fax: +852 2541 1911

© 2022. For information, contact Deloitte China.

Deloitte.

德勤



Life Sciences & Health Care Industry Leading Practices in Industry Expertise

The Deloitte China Life Sciences & Health Care industry team comprises 1,000 practitioners. We serve 91% of the Chinese companies on the Fortune Global 500, and support one-third of the biotech companies that went public on the Hong Kong Stock Exchange.

Our practitioners provide comprehensive solutions for pharmaceutical and biotech companies, medical device manufacturers, and healthcare providers around market access, product launch, commercial excellence, digital transformation, compliance risks, tax planning, and financial management to address the critical industry challenges in today's changing environment.

Scan the QR code to know more about Deloitte Life Sciences & Health Care industry and insights:





Live more,
Bank less

Best Bank in Hong Kong

Achieving more together with you

香港最佳銀行

與您繼續攜手邁向成功

In Hong Kong, our award collections have also been filled with the unprecedented four best bank in Hong Kong's awards in 2022
 星展香港首次獲四份權威金融雜誌一致選定為本年度香港最佳銀行



Hong Kong's Best Bank
香港最佳銀行



Hong Kong's Best International Bank
香港最佳國際銀行



Best International Bank in Hong Kong
香港最佳國際銀行



Bank of the Year - Outstanding Performance
年度銀行傑出大獎

DBS
PRIVATE BANKLive more,
Bank less

DBS Private Bank

Access the best from the World's Best Bank

Best Private Bank - Hong Kong
The Asset Private Capital Awards 2022

Best Asian Private Bank
Asiamoney's Private Banking Awards 2020 - 2022

Asia's Best Bank for Wealth Management
Euromoney's Regional and Country Awards for Excellence 2022

Private Banking - Outstanding
Bloomberg Businessweek - Financial Institution Awards 2022

Best Wealth Manager in Asia
The Asset Private Capital Awards 2020 - 2022

Best Private Bank in Asia Pacific
Global Finance, 2018 - 2023

World's Most Innovative Private Bank
Global Finance, 2018 - 2020, 2022 - 2023

Best Private Bank in Asia
The Banker & PWM Global Private Banking Awards 2018

World's Best Bank
Global Finance, 2018, 2020, 2022

Safest Bank in Asia
Global Finance, 2009 - 2022

記憶力衰退

抑鬱

免疫力下降

失眠

腸胃不適

焦慮

擊退長新冠 增強抵抗力

TRITTICO®

VSL#3®
益生菌

Dicoflor
益生菌



穩定情緒 · 改善睡眠 · 寧心安神 · 促進腸道健康 · 提升免疫力 · 平衡腸道微生物 · 減輕過敏反應

—— 守護健康 · 與李同行 ——

BRIGHT EYES FOR LIFE

ROBUST OPHTHALMIC PIPELINE

6 MAJOR INDICATIONS

**DRY EYE, MYOPIA, PRESBYOPIA,
wAMD, DME AND GLAUCOMA**

**STATE-OF-THE-ART
AND FULLY FUNCTIONAL DEVELOPMENT
AND MANUFACTURING FACILITY
IN GUANGZHOU, CHINA**



Zhaoke Ophthalmology (SEHK: 6622) is a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs in the world.

Zhaoke Ophthalmology has a comprehensive drug portfolio of innovative and generic treatments covering six major eye diseases across both the front and back of the eye. Many of the drugs are being produced in its state-of-the-art and fully functional development and manufacturing facility in Nansha, Guangzhou.

Through our ambitious growth strategy, including partnering with domestic and international pharmaceutical companies, our goal is to become a leader in ophthalmology in China and the world.

For more information, please visit: www.zkoph.com

www.zkoph.com





KOLN3D

CUSTOMIZED ONE-STOP DIGITAL HEALTH SOLUTIONS

PATIENT-MATCHED PRODUCTS

Jigs | Implants | Instruments

KOLN 3D Products improve surgical outcomes with patient-matched and case-specific designs.

Since 2016, over **80 cases** have been successfully conducted with our personalised solutions.

- ✓ Precise
- ✓ Sturdy
- ✓ Bio-compatible
- ✓ ISO 10993-4,5,6 certified
- ✓ ISO 13485:2016 certified
- ✓ ASTM medical-grade materials: ASTM F75, ASTM F136, ASTM F138
- ✓ Speed-up recovery
- ✓ Reduce surgery time

CUTTING JIGS : OVER 60 CASES

OSTEOTOMY SURGICAL JIGS

- ✓ Compact
- ✓ Pressure resistant: 150-350MPa
- ✓ Heat resistant: >700°C
- ✓ Visible under X-ray
- ✓ Protect tissues and blood vessels
- ✓ Clean horizontal cuts
- ✓ Deviation: <1mm
- ✓ Cutting procedure: <15mins



Proximal femur osteotomy



Distal femur osteotomy



Medial malleolar osteotomy



High tibial osteotomy



Spinal osteotomy



Toe corrective osteotomy

ORTHOPAEDIC PSI : PROGRESSIVE INNOVATION

2016
1st Gen



Solid structure
Ensure ankle movability

2018
2nd Gen



Internal super-lattice structure
50% weight reduction

2022
3rd Gen



External porous structure
Promotes osteo-intergration



MANDIBULAR IMPLANT

Temporomandibular joint reconstruction




- ✓ Proprietary gradated osteoinductive porous structure for optimized implant integration
- ✓ Composite UHMWPE-CoCr joint design reduces risk of dislocation
- ✓ Compatible with conventional titanium screws

MAXILLOFACIAL PSI

ORBITAL FLOOR IMPLANT

Orbital and nasal bone fracture repair

- ✓ KOLN3DTi6Al4V Titanium alloy: Sturdy and lightweight
- ✓ Precision additive manufacture: 0.5mm thickness
- ✓ One-stop surgical planning greatly reduces surgery time



Find us on:
medical.koln3d-tech.com

OFFICE:
Koln 3D Technology (Medical) Limited
Room 322, 3/F Core Building 2,
Hong Kong Science Park, Shatin, Hong Kong

WORKSHOP:
Koln 3D Medical Manufacture Limited
Unit 402, 4/F, MARS Centre, 2 Dai Wang Street,
Tai Po, N.T., Hong Kong

EU BRANCH:
Koln 3D Technology SA
Rue de la Pierre-à-Mazel 39, Microcity SA,
2000 Neuchâtel, Switzerland



海康生命科技

HAIKANG LIFE

BioRadar® System

Platform for comprehensive detection of invisible pathogens

系統臨床
產品管線



Infectious
Disease



Cancer



Pediatric
Disease



Orphan Disease

肺炎克星

帶領檢測進入精準時代

多年的發展完善歷程，
進入產業化階段

BioRadar®儀器協助EFADchip®
自動完成檢測操作，避免人為因
素來提高診斷的準確性和精確性。

海康第一款BioRadar®產品
將會是BioRadar® - G系列，
用於基因檢測目的。

海康在BioRadar®系統上已進行多年的
研究和開發，通過一系列設計，搭建和臨床樣品測
試，不斷優化完善，目前第五代BioRadar® - G
已在南沙進行測試，步入產業化階段。

Hai Kang Life Corporation Limited (Headquarters)

Add: Units 601-605, 6/F, Biotech Centre One, Hong Kong Science Park, Shatin, New Territories, Hong Kong, P.R.China

Tel: +852 2111 2123 | Fax: +852 2111 9762 | Email: info@haikanglife.com

Welcome Message from Presidents

Dear Biotechnology Enthusiasts,

Hong Kong has opened its borders to the world! Once world-renowned as Asia's top financial center, Hong Kong has spent the past two years utilizing the power of biotechnology in resisting this pandemic and is experiencing significant demographic shifts; these events are spurring Hong Kong's emergence as a new player in innovative healthcare. With quarantine restrictions removed, now is the best time to register and catch up with the latest information about the biotechnology industry at our BIOHK2022 International Convention!

In recent years, biotechnology has emerged as one of the fastest-growing sectors in Hong Kong and China. Recognizing its potential, the government has offered strong support through investment in research and development and the building of infrastructure to foster close connections between industry, academia, and investors. According to the Research Grants Council, between 2013/14 and 2017/18, 803 biotechnology-related projects in local universities were publicly funded amounting to HK\$1.2 billion, while outside of academia, through the Innovation and Technology Fund, over 460 biotechnology projects have been funded including those related to non-invasive prenatal diagnosis, robotics-assisted minimally invasive surgery and mini artificial heart.

Hong Kong is considered the gateway to China due to its unique status as a special administrative region, which offers a rich source of opportunities for overseas investors looking to capitalize on the continued growth of the Greater Bay Area (GBA) — a scheme initiated by the Chinese government to link Hong Kong, Macau and 9 other cities along the Pearl River Estuary and form an international technology and innovation center rivaling that of Silicon Valley. With its strong exposure and international integration, Hong Kong has become the go-to stepping stone for Chinese companies looking to expand abroad. New listing rules adopted by the Hong Kong Stock Exchange (HKEX) allowed pre-revenue biotech companies to be listed on the exchange, turning the city into Asia's largest biotech fundraising hub. A first in Asia, it ensured more capital could flow freely towards a sector that'd been largely deprived in the region until recently. As such, owing to its geopolitical advantage, a large

number of world-class universities, and its reputation as the No. 1 biotech IPO market in Asia, Hong Kong is a safe harbor for global investors to reap benefits at the epicenter of Asia's biotech revolution. It is our hope that BIOHK2022 will help set this in motion.

Hong Kong's position in the Greater Bay Area enables companies to tap into vast pools of talent and funding in mainland China. COVID-19 has accelerated the growth of the biotechnology industry and expanded its impact on solving humanity's biggest health problems. From new drug developments to mRNA vaccines, emerging state-of-the-art biotechnologies are timely reminding the world of its importance, highlighting its key role in ending this pandemic and opening Hong Kong's borders. It is our mission to showcase these advancements and foster collaboration at BIOHK2022.

We are aiming to bring you the world-class biotech convention. Our BIOHK2022 Presidents are from different disciplines of biotech spanning over 20 years from academia to venture capital. BIOHK2022 will be one of its kind — all the modern biotech elements on display to bring you a full range of biotech to discover. Business opportunities are best made face to face and BIOHK2022 will foster one of the first large-scale networking opportunities in December 2022. We have worked tirelessly for this moment to unite people from all over the world to participate in our event to ensure the event is an overwhelming success.

As a city with a rich history in industrial development and innovation, and one that is frequently coined "Asia's World City", there is no better place to bring biotech companies from East and West together other than here at BIOHK2022. Take charge and seize the many opportunities available and engage with global industry leaders at BIOHK2022.

With the successful development and popularization of the coronavirus vaccine, we believe that technology can take everyone out of the predicament. We look forward to seeing you in BIOHK2022.

Yours sincerely,
YU Cheung-Hoi, Albert
YU Guo-Liang
CHEN Ping
(Co-Presidents, BIOHK2022)



Structure of Organising Committee

Presidents

Prof. YU Cheung-Hoi, Albert	Co-Presidents, BIOHK2022
Dr. YU Guo-Liang	Co-Presidents, BIOHK2022
Mr. CHEN Ping	Co-Presidents, BIOHK2022

Vice Presidents

HU Charles	Founder & CEO, Ryoden Medical & Transformation Biotechnology Entrepreneur
LEUNG Chuen-Yan	Hai Kang Life Corporation Limited & Vice President, EQT Group
LI Benjamin	Chairman & CEO, Zhaoke Ophthalmology Limited in Lee's Pharmaceutical (HK) Limited
WAN Mu, Maki	Past President, Rotary Club Kowloon Golden Mile
WONG Tat-Tong	President, Greater Bay Area Biotechnology Alliance

Advisor Convenor

WONG Kennedy	National Committee Member, Chinese People's Political Consultative Conference Member, Legislative Council of The HKSAR Member, Election Committee of The HKSAR Managing Partner, Philip K.H. Wong, Kennedy Y.H. Wong & Co.
--------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vice Advisor Convenor

CHAN Yung	Deputy, the 12 & 13th National People's Congress of the People's Republic of China; Member, Legislative Council of the HKSAR; Vice Chairman, DAB (Democratic Alliance for the Betterment and Progress of Hong Kong); Chairman, NTAS (New Territories Association of Societies)
-----------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Advisors

CHAN Pui-Leung	Member of Legislative Council; General Manager of China Taiping Insurance (HK) Co Ltd
CHAN Siu-Hung	Member of the Legislative Council
GUO Yi-KE	Provost, The Hong Kong University of Science and Technology
HO Shun-Man	President of The Hang Seng University of Hong Kong
HONG Wendy	Member of the Legislative Council

Advisors

HU Herman	Deputy, the 12th & 13th National People's Congress of the People's Republic of China
HUNG Witman	Deputy, the 13th National People's Congress of the People's Republic of China
IP LAU Suk-Yee	Convenor of the Non-Official Members of the Executive Council; Member of the Legislative Council; Chair of the New People's Party
JIANG Jasper	Founding partner, Tiger Jade Capital
KAN Carmen	Legislative Council Member; Solicitor; General Counsel
KOON Peter Douglas	Legislative Council Member; Clergy
LAM Chun-Sing	Member of Legislative Council; The Federation of Hong Kong and Kowloon Labour Unions — Chairman
LAM Lung-On	Deputy, the 13th National People's Congress of the People's Republic of China; President of the Hong Kong Chinese Importers' & Exporters' Association
LAM San-Keung	Legal Functional Constituency — Member of Legislative Council
LEE Chun-Keung	Legislative Council Member
LEE Kwan-Ho	Deputy, the 13th National People Congress of the PRC; Member, the Hong Kong Election Committee; Chairman, the Tung Tai Group of Companies
LEE Simon	Legislative Council Member
LEUNG Andrew	President, Legislative Council; Business and Professionals Alliance for Hong Kong
LEUNG Dennis	Legislative Council Member; Community Officer
LEUNG Siu-Fai	Director of Agri., Fisheries & Conservation; Director of Marketing, Regr of Co-op. Soc., Regr of Credit Unions
LIU Da	Managing Director, CR CP Life Science Fund
LIU Shi-Ming	First Class Inspector of the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region and Chief Representative of the Ministry of Science and Technology in Hong Kong, Deputy Secretary General, China Invention Association
LUK Benson	Legislative Council Member
MA Fung-Kwok	Legislative Council Member
NG Jimmy	Functional Constituency — Industrial (Second)
QUAT Elizebeth	Member of the Legislative Council
Rainer Jungjohann-Ott	Member of AHK, German Chamber, Hong Kong
SIT Allen	President of the Chinese Manufacturers' Association of Hong Kong
SIT Wing-Hang	Former Secretary for Innovation and Technology
SO Chi-Ki	Executive Director, Hong Kong New Generation Cultural Association

Advisors

TAN Henry	Deputy, National People's Congress, PRC, Textile Council of Hong Kong — Chairman; Luen Thai Group Ltd — Vice Chairman & Chief Executive Officer
TANG Fei	Legislative Council Member
TING Bernie	Chairman, PRD Council
TUAN Rocky S.	Vice-Chancellor and President of The Chinese University of Hong Kong
WONG Stephen	Legislative Council Member; Our Hong Kong Foundation, Senior Vice President & Executive Director of Public Policy Institute
YANG Michael	Vice-President (Research and Technology), City University of Hong Kong
YUNG Hoi-Yan	Legislative Council Member; Barrister-at-law

Legal Advisors

DE Theresa	Managing Partner at Jun He Law Offices
UNG Monin	Legal Advisor, Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Managing Partner, MUNG Legal
WONG Yu-Ngai	Assistant Solicitor • Philip K.H. Wong, Kennedy Y.H. Wong & Co.; 30th Board of Directors / Deputy Secretary of Hong Kong United Youth Association

Financial Advisors

LAU Franklin	CEO of Reanda International Accounting Network
--------------	------------------------------------------------

Committee Members

BA Su-Juan	President and CEO, National Foundation for Cancer Research
CAO Jing-Hua	Executive Director, ANSO Secretariat, Alliance of International Science Organizations
CHAN Albert	KINECT LAW™ — Principle
CHAO C. K.	Managing Director, CK Hair International Ltd
CHAU Wilton	Chairman, Pan Asia Venture Development Platform (PAVD)
CHEN Danny	Investment Director, Affix Capital
CHEN Michelle	Chief Business Officer, Insilico Medicine
CHEN Tony	Partner, Jones Day
CHEN Xin, Lorna	Asia Regional Managing Partner and Head of Greater China, Shearman & Sterling

Committee Members

CHENG Gordan	Chief Executive Officer, Cameron Pace China Limited
CHOW Larry	Director, Research and Innovation, PolyU
CHOW Ralph	CEO, Chinese Manufacturers' Association of Hong Kong (CMA)
CHOW Yiu Ming	Chief Financial Officer, Lee's Pharmaceutical Holdings Limited
CHUNG JOHN	Former Superintendent, Hong Kong Police Force
GOH Terence	Executive Director, DBS Bank (Hong Kong) Limited
HAO Martha	Chairman, Hong Kong Medical and Healthcare Device Industries Association
HAU Desmond	CEO, Pangenix Inc.
HSIAO Wendy	Professor, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology
HSU Hoi-Shan	Beijing-Hong Kong Academic Exchange Center, Director
JE Simon	Chairman of the Board, Great Treasure International / Galaxy Treasure Group
JIANG Claire	CEO, Queens (Shenzhen) Biotechnology Co., Ltd.
JIANG Gina	Managing Director, Hong Kong Institute of Biotechnology (HKIB)
JIANG Ru-Hong	Founder, President and CEO, ASC Therapeutics, Inc.
LAM Stephen	Director, Clinical Genetics Service, Hong Kong Sanatorium & Hospital
LAW Philip	Lead Partner, Venture Capital & Private Equity, Deloitte
LE DEU Franck	Senior partner, McKinsey & Company, Co-leader of Asia Life Sciences practice
LEE Tin-Lap	Associate Professor, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
LEUNG Thomas	Lo Ka Chung Charitable Foundation Professor in Pharmaceutical Sciences Professor and DoULS
LI James	President, LiLaw Inc.
LI Shan	Partner, Summer Capital
LI Ying	Chair Professor of Neuroscience, City University of Hong Kong
LIN Min-Din	CEO & Editor in Chief, Global Bio & Investment Monthly
LIU Andy	President, Healthcare Division, BaseBit Technologies
LO Kitty	Chairman and CEO, Finet Group Ltd
LO Yuk-Lam	Chairman, Food and Environmental Hygiene, Food and Health Bureau, Government Secretariat HKSAR

Committee Members

LU Ming-Hua	Founding Partner, eChinaHealth
LYU Ai-Ping	Dean and Chair Professor, School of Chinese Medicine, Hong Kong Baptist University
MOK John	Chairman, AML Holdings Limited
Montelius Lars	Director General, International Iberian Nanotechnology Laboratory
Nearing A. Kimberly	Venture Partner, Bvcf Management, Ltd
ORR Kevin	Vice President, Winner Medical Group
PAN Wendy	Partner, Goodwin's Technology & Life Sciences group
PEI Duan-Qing	Principle Investigator and Academic Director at the Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences
QIAN Pei-Yuan	Head and Chair Professor, Department of Ocean Science, Hong Kong University of Science and Technology
Segerblom Bjorn	Honorary Chairman and Hong Kong Representative, International Iberian Nanotechnology Laboratory
SHAN Mai-Har	Vice-President, The Chinese University of Hong Kong
SHANG Hai-Long	Managing Director, SenseTime Hong Kong
SHI Victor	CEO, Adicon Clinical Laboratories
SIU Eric	Idea Excel International Enterprise Limited — Founder and Chief Executive Officer
SUN Fei	Assistant Professor, Chemical and Biological Engineering, The Hong Kong University of Science and Technology
SUN Nan	Deputy Inspector, Shenzhen Association for Science and Technology
SUN-HOFFMAN Lin	Head of the North California Division, BayHelix
TAM Paul	Director, Dr. Li Dak-Sum Research Centre
TANG C. Mark	Managing Director, Good Health Capital (New York)
TIAN Yao-Lin	CEO, ShenZhen Govita Medical Laboratory
TSIM Karl	Director, Center for Chinese Medicine Research and Development, The Hong Kong University of Science and Technology
TSUI Victor	COO, Powder Pharmaceuticals Incorporated
WANG Ji-Guang	Assistant Professor, Division of Life Science, The Hong Kong University of Science and Technology
WANG Jing	Center for Advanced Measurement Science, National Institute of Metrology, China
WANG Yi-Tao	Director, Institute of Chinese Medical Sciences, University of Macau
WONG Bing-Lou	Adjunct Professor, Department of Biochemistry, Chinese University of Hong Kong

Committee Members

WONG Kenneth	Chairman and CEO, Keen Vision Capital
WONG Vivian	Hon Professor, School of Chinese Medicine, The University of Hong Kong
WU George	Corporate partner, DLA Piper Hong Kong
XIE Jia-Sheng	Director & Executive President, Guangdong Medical Valley (GDMV)
YANG Hai-Ding	Executive Director and Founding Team Leader, Healthcare sector of Cathay Capital
YANG Ling	Managing Director, The Carlyle Group
YANG Ray	Partner, Marathon Venture Partners
YANG Steve	Chief Business Officer & Executive Vice President, WuXi AppTec Co., Ltd.
YAO Michael	Former Senior US FDA Clinical Assessment Officer
YAU Edmond	Founder & CEO, Koln 3D Technology (Medical) Limited
YIP Raymond	Vice Chairman, Belt and Road Global Development Alliance
YU Duncan	President, MGI
YUNG Ken	Professor and Associate Head, Department of Biology, Faculty of Science, Hong Kong Baptist University
ZHANG Jimmy	Founding member, Former Chairman of BayHelix Group
ZHENG Lili	Partner, Deloitte Tax LLP
ZHONG Sharon	Banker, J.P. Morgan Private Bank
ZHOU Grace	President, Shenzhen International Institute for Biomedical Research
ZUO Joan	Vice-president, The Society of Hong Kong Scholars

Art Director

TANG Tat-Chi, William

Hong Kong Fashion Designer

Brand Director

LEUNG Fung Yi, Joey

Founder & CEO, AIFA TECH LIMITED

Ambassadors

CHAN John

Head of Strategic Development Ample Capital Limited

Ambassadors

CHAN Paul	Chairman, Wellink International Accounting Group
CHOW Joseph	Hongkong APX Capital Partner
DONG Li	Funding Partner of Wellington Legal
Jagetiya Avinash	Managing Director of Sun Management Group (Reanda UAE)
Jagetiya Sunil	Chairman and Founder of Sun Management Group (Reanda UAE)
KOONG Lin-Loong	Managing Partner, Reanda LLKG International Chartered Accountants
LIAO Cecilia	MCIARB DPA, PGDBA, BA. (Hons) UK
PANG Karen	Founder & CEO of Meheal Healthcare Co., Ltd. Executive Director of BHT Advisory Pte Ltd.
Peter J. Polgar	Executive Chairman of Reanda Australia Pty Ltd.
YEUNG Francis	Founding member of Supreme Life Science Limited. Senior: Advisor to Sure Success Limited

Names and affiliations were provided by members
 If there are any typos and mistakes, Please contact with HKBIO, secretary
 Wendy Huang at Phone No. 2111-2123

Program Information

Event Title: BIOHK2022

Organizers: Hong Kong Biotechnology Organization
The BayHelix Group
Ausvic Group

Date: Dec 14 - Dec 17, 2022

Venue: Hong Kong Convention and Exhibition Centre

Website: bio-hk.com

// Floor Plan //



Exhibitor List

A Plus Healthcare Development Limited	迦德誠醫療發展有限公司	B01-02
Agilent Technologies Hong Kong Limited	安捷倫科技香港有限公司	Q04
Agilis Robotics Limited	巧捷力醫療機器人有限公司	P05
AlpaLife (Shenzhen KangTi Life Technology Co., Ltd)	深圳康体生命科技有限公司	P03
AlphaHygienic Co. Limited		Q13-14
AP Infosense Limited	愛佩儀傳感信息科技有限公司	C03
ASIAN FUND FOR CANCER RESEARCH LIMITED	亞洲癌症研究基金會有限公司	A07
Beijing Airdoc Technology Co., Ltd	北京鷹瞳科技發展股份有限公司	Q06-07
BETH Bioinformatics Co. Ltd	貝思生物科技有限公司	P01
BGI Health (HK) Company Limited	華大基因健康科技(香港)有限公司	N01
Bioprobes Ltd.	拜譜有限公司	C07
CaTAGene Limited		P11-12
Centre for Novostics Limited	創新診斷科技中心	M03
Certizen Technology Limited	翹晉科技有限公司	C02
China Biotech Services Holding Limited	中國生物科技服務控股有限公司	M01-02
City University of Hong Kong	香港城市大學	H01-06, J01-06
Clinixir Company Limited		Q08
CMB Wing Lung Bank Limited	招商永隆銀行	A05
College of American Pathologists	美國病理學會	B09
Crystal Peace Health Science Limited	晶寧科研保健有限公司	C01
D&D Electronics Co., Ltd	D&D電子	C05
DBS Bank (Hong Kong) Limited	星展銀行	A01
Deloitte China	德勤中國	K03-04
DreamTec Ltd.	夢芊科技有限公司	L01-02
Eagle IP Limited	鷹翅知產有限公司	C09
East Fortune Technology Limited	富東科技	L15-16
eNano Health Limited	依納康科技有限公司	M07
Eversana Hong Kong Limited		Q05
Gallant Biotechnology Limited	嘉倫生物科技有限公司	M08-09, N08-09
GenieBiome Limited	精進微生物科技有限公司	L08-09, K08-09
GenScript Biotech (Singapore) Pte Limited	金斯瑞生物科技	B04-05
Gense Technologies Limited	尖思科研有限公司	P02
Greater China Corporate Consultancy & Services Limited		N03
Green Life Technology Ltd.		Q02
Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance		F01-04, G01-04
Guangzhou Nansha Service Centre in Hong Kong	廣州南沙新區香港服務中心	N12
H&W Group (Greater China) Limited	富康集團	L13-14
Hai Kang Life Corporation Limited	海康生命科技有限公司	D08-09, E08-09
Hainan IEDB Hong Kong Branch	海南國際經濟發展局駐香港辦事處	N13
Health Advances Asia Ltd.		B07
HK Council for Testing and Certification (CTC)	香港檢測和認證局	N07

HK-Dtech Limited		M04
HKG Epitherapeutics Ltd.	香港精準醫學技術有限公司	B08
Hong Kong Center for Clinical Research	香港臨床研究中心	K01-02
Hong Kong Cyberport Management Company Limited	香港數碼港管理有限公司	D07-E07
Hong Kong Institute of Biotechnology Limited	香港生物科技研究院有限公司	H07
Hong Kong New Generation Cultural Association (HKNGCA)	香港新一代文化協會	Q09
Koin 3D Technology (Medical) Limited	科能三維技術(醫療)	F08-09, G08-09
Immune Materials Limited	易新材料有限公司	C06
Immuno Cure Holding (HK) Limited	醫克生物控股(香港)有限公司	N05-06
InCompass IP Limited	因可保有限公司	B03
Insilico Medicine Hong Kong Limited	英矽智能	C04
Intellectual Property Department, the Government of the HKSAR	知識產權署	B06
Invest Hong Kong	投資推廣署	C08
Jiangsu Cowin Biotech Co., Ltd.	康為世紀生物科技股份有限公司	N04
Lee's Pharmaceutical (HK) Limited	李氏大藥廠	E04-06
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited	兆科眼科	D04-06
Mattey Supply Company Limited	美譽創健有限公司	J13-14
Max Choice Corporation Limited		P08
MGI International Sales Co.Ltd.	華大智造	K05
Midland Financial Group	美聯金融集團	H11-12, J11-12
Nano and Advanced Materials Institute Limited	納米及先進材料研發院有限公司	D01-03, E01-03
OrbusNeich Medical Company Limited		K12-14
Phase Scientific International Ltd.	相達生物科技	Q03
Rehab- Robotics Company Limited		K15-16
Sanwa BioTech Limited	三和生物科技有限公司	L03-04
School Of Chinese Medicine Hong Kong Baptist University	香港浸會大學中醫藥學院	K06-07
Sense Time Group Limited	商湯科技	P06-07
Sunrise Diagnostic Centre Ltd.	華昇診斷中心有限公司	N02
Taoist Culture of Healthy Living Association Ltd.	中道養生醫術學會有限公司	P04
The Chinese University of Hong Kong	香港中文大學	H08-09
The Commercial Press (HK) Ltd.	商務印書館(香港)有限公司	Q01
The Hong Kong Branch of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)	南方海洋科學與工程廣東省實驗室(廣州) 香港分部	J09
The Hong Kong Polytechnic University	香港理工大學	M14-15
The Hong Kong University of Science and Technology	香港科技大學	J07-08
Tiger Jade Capital, LLP	泰欣資本	A03
Tinhankin Pharmaceutical Limited	天行健醫藥有限公司	P09
U.S. Pacific Nonwovens Industry Limited	美亞無紡布工業有限公司	M13, N11
Yuanhua Robotics, Perception & AI Technologies (HK) Ltd.	元化智能科技(香港)有限公司	K11
ZSHK Laboratories Ltd.	滬港中科國際生物科技有限公司	Q11-12
	深圳市前海香港商會	P13-14
Greater Bay Area Biotech Alliance	粵港澳大灣區生物科技聯盟	L17 & K17

Exhibition

- Pitch and Connect -

The exhibition is a platform for early stage spin-outs and established firms in all areas including healthcare to pitch their visions backed by the strength of customized branded exhibits. It is a perfect opportunity to make meaningful in-person business connections with senior level management and investors. Filled with the latest trends, technology, companies, and breakthrough ideas in biotechnology and pharmaceutical, this exhibition must not be missed.

Conference and Pitching

- Share and Inspire -

It is a platform for investors, entrepreneurs, leaders and international scientists to have in-depth discussions and share on latest regional and international researches as well as findings. You can exchange ideas, professional experience across a wide range of topics in different sessions, panel discussions and podium talks. There is no language barrier as the conference will provide simultaneous interpretation supporting English, Cantonese and Mandarin.

One2One Partnering

- Promote and Establish -

Bringing the world together to navigate and capitalize on the opportunities in Hong Kong as burgeoning biotech hub, it intends to aid attendees in identifying and connecting prospective partners in the form of investors, analysts and partnering companies for future collaborations. Align your goals and maximize your returns with other parties in the future of biotech.

Day 1

Main Theatre 5/F

14 DEC 2022

9:00-9:30

Opening Ceremony

MC: HU Charles, BIOHK Vice President

9:30-10:00

KEYNOTE SESSION 1:

LEUNG Chun Ying, Vice Chairman, NCCPPCCChair: YU C-H Albert, HKBIO Chairman, HKLife Chairman, BIOHK2022 Co-President

10:00-10:30

KEYNOTE SESSION 2:

Building Bio Economy: Next Growth Factor for Hong Kong based on Public Interest CapitalismAmbassador Hara George, Chairman & CEO, DEFTA PartnersChair: YU C-H Albert, HKBIO Chairman, HKLife Chairman, BIOHK2022 Co-President

10:30-11:00

KEYNOTE SESSION 3:

Strategy for Life Science and Biotech Companies under New ChallengesYU Guo-Liang, Chairman, Bayhelix & Co-President, BIOHK2022Chair: Li Benjamin, BIOHK2022 VP

11:00-11:30

KEYNOTE SESSION 4:

New Horizons to Advance Cancer Research through Impact Investment and Global CollaborationLance Kawaguchi, Chairman, AFCRChair: Li Benjamin, BIOHK2022 VP

Day 1

Main Theatre 5/F

14 DEC 2022

KEYNOTE SESSION 5:
Translating RNA from Bench to Bed and Beyond
11:30-12:00 DAI Xiao-Chang, Executive Director, Sirnaomics
Chair: LEUNG Chuen-Yan, BIOHK2022 VP & Vice President, EQT Group

KEYNOTE SESSION 6:
Hong Kong as a Global Leading Fundraising Hub for Healthcare Industry
12:00-12:30 YIU Wilfred, Chief Operating Officer & Co - Head of Markets, Hong Kong Exchanges and Clearing Limited
Chair: LEUNG Chuen-Yan, BIOHK2022 VP & Vice President, EQT Group

KEYNOTE SESSION 7:
Non-invasive prenatal testing and other liquid biopsies: from dream to reality
14:00-14:30 LO Dennis, Professor, CUHK
Chair: LEUNG Chuen-Yan, BIOHK2022 VP & Vice President, EQT Group

Day 1

Main Theatre 5/F

14 DEC 2022

WORKSHOP 1: POLICY**Five year plan for Biotech in Hong Kong and GBA**

Chair:

WONG Kennedy, National Committee Member,
Chinese People's Political Consultative ConferenceCHEN Ping, Founder of Ausvic Capital LimitedYU C-H Albert, HKBIO Chairman, HKLife Chairman,
BIOHK2022 Co-President

Opening speech:

TSANG Arthur, Research in Tech Innovation at Our
Hong Kong Foundation

14:30-17:00

Panelists:

CHAN Sabrina, HKAPILO Yuk-Lam, Founding President of HK Bio-Med
Innotech AssociationHU Charles, CEO of Ryoden Medical HoldingsWU Shan, General Manager, AstraZeneca Hong Kong
LimitedCHAU Wilton, Chairman, Pan Asia Venture
Development PlatformYU Guo-Liang, Chairman of BayhelixLIU Da, Managing Director, CR CP Life Science Fund

Day 1

Town Hall 5/F

14 DEC 2022

FORUM 1: Special Forum

11:00-12:30

GBABA Advocacy Summit: Integration into the National Development; Hong Kong Biotechnology Industry in Prospect***Invitation only***

PLENARY PRESS CONFERENCE

14:30-15:30

Deloitte x HKBIO**China Life Sciences and Health Care M&A Market outlook**

SPECIAL WORKSHOP

15:30-17:00

Pitching Training for Start-upsDesmond Marshall, Managing Director,
Rouge Ventures

Day 1

SYMPOSIUM 5/F

14 DEC 2022

SYMPOSIUM 1: The future of healthcare through the eyes of ophthalmology (Zhaoke sponsor)Chair: TSAI Albert, CMO, Zhaoke

14:30-15:30

Topic: **Landmarks in Ophthalmology**LEUNG Christopher, Clinical Professor, HKUTopic: **Ophthalmology as a role model for decentralization of healthcare**CHEN Andrew, Managing Director, AccentureTopic: **Future of Ophthalmology therapeutics**LEI Zhou, Professor, HKPU**SYMPOSIUM 2: GBA investment**Chair: Tang Mark, Managing Director, Health Capital

15:30-17:00

Topic: **Fundraising for early stage ventures**CHAU Wilton, Chairman, PAVDTopic: **Alternative Financing Options for Private and Public Global Chinese Biotech Companies in the US**TANG Mark, Managing Director, Health CapitalTopic: **Biotech & Medical Device Industry Development in Shenzhen**DONG Li, Hongkong APX Capital PartnerTopic: **Strategic Approach to IP protection for Biomedical Innovations in GBA and China**CHE Jennifer, Vice President, Eagle IP Limited

Day 2

Main Theatre 5/F

15 DEC 2022

KEYNOTE SESSION 8: Patient Characterization for Scalable and Accurate Identification

9:00 - 9:30

GUO Yi-Ke, Provost, Hong Kong University of Science and TechnologyChair: LEUNG Chuen-Yan, BIOHK VP & Vice President, EQT Group**KEYNOTE SESSION 9: What does quantum science have to do with biotech?**

9:30 - 10:00

CHAN Garnet, Professor, California Institute of TechnologyChair: LEUNG Chuen-Yan, BIOHK VP & Vice President, EQT Group**FORUM 2: Banking for Biotech (DBS sponsor)**

10:00 - 11:45

Topic: Family Offices in a Changing World - The Value Proposition to TechnopreneursLEE Woon Shiu, Group Head, DBSCHEN Joy, Partner, Ernst and Young Global LtdWONG Dixon, Head of Financial Services, InvestHK**Topic: China Macro 2023: Rationalisation of dual circulation strategy**LEUNG Chris, China Chief Economist, DBSTSE Samuel, Macro Research Economist, DBS

Day 2

Main Theatre 5/F

15 DEC 2022

ROUNDTABLE 3: Capital Market for Healthcare Post Pandemic (SCMP/HKEx sponsor)

Moderator: WONG Olga, Deputy Hong Kong Editor, SCMP

11:45 - 12:30

LI Bin, Founder and CIO, Lake Bleu Capital

WANG Yin-Xang, Chairman and CEO, Jacobio

Vijay Karwal, CFO, AffaMed Therapeutics

LUNG Donald, CFO, Antengene

KEYNOTE SESSION 10: Mathematical Theory about deep neural networks and application to medical and biomedical problem

14:00 - 14:30

Chair: WAN Maki, Former President, Rotary Club Kowloon Golden Mile

TAI Xue-Cheng, Chief Research Scientist and Program Director, Hong Kong Centre for Cerebro-Cardiovascular Health Engineering, Hong Kong Science Park

**KEYNOTE SESSION 11:
Umbilical Cord Blood Exosomes**

14:30 - 15:00

Chair: PANG Chris, Founder & CEO, ART Quant

YOUNG Wise

Professor, Rutgers University

Day 2

Main Theatre 5/F

15 DEC 2022

PLENARY 5: Revolutionising Microbiome biotechnology

15:00 - 15:30

Chair: Chris Pang, Founder & CEO, ART QuantTopic: **Making IT happen**NG Siew-Chien, Assistant Dean, Chinese University of Hong Kong**PLENARY 7: Regenerative medicine**Chair: YAO Michael, Former Senior US FDA Clinical Assessment OfficerTopic: **Stem cell therapy for retinal degenerative diseases: hope and challenge**XIE Ting, Head of Life Science, Hong Kong University of Science and Technology

15:30 - 18:00

Topic: **From Poison to Paragon**TSUI Joseph, Professor, University of British ColumbiaTopic: **Implantable photomedicine for cancer and neurodegenerative diseases**HU Charles, Co-Founder, Incando TherapeuticsTopic: **ATP GMP FACILITY: passage to Hong Kong's Future**JIANG Gina, Managing Director, Hong Kong Institute of Biotechnology

Day 2

Town Hall 5/F

15 DEC 2022

8:45-11:00

WORKSHOP 2: A Path Forward for Cancer Eradication in Hong Kong

Invitation only

11:00-12:30

PLENARY SESSION 2: CancerChair: BA Su-Juan, President and CEO, National Foundation for Cancer Research.**Topic: WT1 cancer vaccine for the treatment and prevention**SUGIYAMA Haruo, Professor, Osaka University**Topic: Genetically engineered viral vector and non-viral nanocarriers for drug delivery applications**ZHOU Grace, CEO, ImmVira**Topic: DNA methylation a “paradigm-shift” in early prediction of cancer and other diseases**Moshe Szyf, Founder, HKG Epitherapeutics**Topic: Unlocking the promise of viral vector and non-viral vector for gene and cell therapy**WONG Edward, Product manager, Genscript

Day 2

Town Hall 5/F

15 DEC 2022

PLENARY 4: Advanced Technologies in Drug Development

Chair: TANG Mark, Managing Director, Good Health Capital

Topic: **New generation: AI empowers drug discovery and precision medicine**

WANG Xin, Department of Surgery, Faculty of Medicine, CUHK, Consultant, SenseTime

15:00 - 17:00

Topic: **AI-driven target identification for drug development**

PUN Frank, Head of Hong Kong Office, Insilico Medicine

Topic: **Immuno Cure – Bringing Innovative Vaccines and Immunotherapies to People**

JIN Xia, CEO, Immuno Cure

Topic: **Epicardial patches for heart failure**

ZENG Yi-Jun, CEO, Nanoheart Med Tech

17:00-18:00

Snapshot Pitching

Midland Financial Group

Greater China Corporate Consultancy & Services Limited

Day 2

SYMPOSIUM 5/F

15 DEC 2022

SYMPOSIUM 3: Polymer Innovation for Medical Advancement and Environmental Sustainability (NAMI sponsor)

Chair: CHAN Priscilla, NAMI

Topic: NAMI – Your Material Expert on Innovative Solutions

CHAN Priscilla, NAMI

10:00-11:15

Topic: Cost-competitive Micro-foaming Pellets for Heavy Duty Plastic Foams

CHEN Yvonne, NAMI

Topic: Built-in, Leach-free Antimicrobial Polymeric Materials

CHOW Man-Tung, NAMI

Topic: Fighting Hard Medical Problems with Soft Hydrogels

TANG Shawn, NAMI

ROUNDTABLE 2: How to hunt Life Science Unicorns

Moderator:

LIU Da, Managing Director, CR CP Life Science Fund

Panelists:

11:15-12:30

HUA Simon, Chairman, China Finances Strategies Investment Holdings Limited

Rita Shih, Vice President, HK R&D Centre, New Horizon Health

LAW Martin, Managing Director, MiRXES Hong Kong Limited

YIP Nigel, CFO, Sirnaomics

Day 2

SYMPOSIUM 5/F

15 DEC 2022

PLENARY 6: Ocean Biotech

15:00-16:00

Topic: Antibiotics discovery from the untapped ocean microbiomeLI Yong-Xin, Asst Prof. HKU**Topic: Drug Discovery for Neurodegenerative Diseases: from Sea to Pharmacy**CHENG Ai-Fang, RAP, HKUST**PLENARY 8: Infectious diseases**

16:00-18:00

Chair ZUO Joan, Director, School of Pharmacy, Chinese University of Hong Kong**Topic: Integrated Healthcare Management in a Post-COVID Era**CHIU Jenny, General Manager, PHASE**Topic: Development of PD-1 Enhanced DNA Vaccines for Infectious Diseases and Beyond**KWONG Thomas, Research Scientist, Immuno Cure Holding (HK) Limited**Topic: Development of an effective protein-based Covid-19 vaccine forms for Infectious Diseases and Beyond**Fabrizio Maria Anella, Senior RS, Taron Solutions**Topic: Complete diagnostics solution for COVID-19**HUNG Jacob, DNA-Tech**Topic: Safety and Immunogenicity of Inactivated Bacillus subtilis Spores Surface Fraction as a SARS-COV2 Neutralizing Antibody Booster**KWONG Keith, CSO, Dream Tec

Day 2

Room S421 4/F

15 DEC 2022

PLENARY 1: What's ahead for Biotech?Chair: WONG Bing Lou, CSO, Bing Biotech**Topic: ESG in Biotech: Driving towards a more Sustainable Future**Mohit Grover, Deloitte AP LSHC Risky Advisory Leader**Topic: Traditional Chinese Medicine Based Combination Drug Discovery Platform Powered By Artificial Intelligence**Nuzhat Tam-Zaman/ TAM Yun K, Co-Founder, Sinoveda**Topic: Anticipating and adapting at every step of clinical development**

10:00-12:30

Luis Segovia Sordo, Director, Parexel**Topic: Biotech Funding in Asia and the US in 2023 and Beyond**CHENG Gary, Vice President, Health Advances**Topic: Latest development on Nansha Biotech**YIP Raymond, Chief Liaison Officer, Nansha New Area**Topic: New ways to Commercialise in the US and EU for Higher Value**Mungo Paterson, Senior Director, Sales & Business Development, EVERSANA Asia Pte Limited**Topic: Emerging Opportunities for Biomaterials**CHAU Ying, Professor, HKUST

Day 2

Room S421 4/F

15 DEC 2022

FORUM 3: CAP Laboratory accreditation (CAP sponsor)Chair: LIU Yuan

15:00-16:00

Topic: Your Path to Laboratory Quality Excellence - Introduction to the College of American Pathologist Laboratory Accreditation Program
MA Li-Bin, Labcorp**ROUNDTABLE 4: How Hong Kong will become Asia's Biotech Innovation Centre (Tiger Jade sponsor)**Moderator: HUI Emmanuel, CEO of Tiger Jade Pebble Accelerator

16:00-17:00

Panelists:

WANG Jack, Partner, Tiger Jade CapitalLEUNG Kingsley, CEO, Great Bay BioSIU Patrick, CEO, Hong Kong-Shenzhen Innovation and Technology Park**----- Attention -----**

Due to demand, Some events were relocated to 4th Floor of Convention Center Room S421 and S428.

Day 2

Room S428 4/F

15 DEC 2022

ROUNDTABLE 1: **Value of CAP accreditation (CAP sponsor)**

10:00-11:15

Panelists:

LIU Albert, General Manager, BGI Health (HK) Company Limited

Moshe Szyf, HKG epiTherapeutics Limited

LOO Wings, DNA Wecheck Limited

LEE Wai-Chung Kirsty, Sanomics Limited

MA Li-Bin, Labcorp

PLENARY 3: **Advanced Technologies in Diagnostics**

Chair: LEUNG Chuen-Yan, BIOHK2022 VP & Vice President, EQT Group

Topic: **Novel portable electrical impedance tomography system enables home-based biomedical imaging for preventive screening**

CHAN Russell, Co-founder and CTO, Gense Technologies Limited

11:15-12:30

Topic: **BioRadar: A revolutionary solution towards 'Point-of-Care'**

ZHAN Jiang-Shan, CSO, Hai Kang Life

Topic: **Elementomics in health and disease and its application in sperm quality assessment and fertility diagnosis**

SHUM Winnie, Founder&CSO, Elementomi Analytics and Diagnostics Limited

Topic: **In vitro diagnostics: safety and performance**
WONG Veronica, Regulatory Affairs Manager, Sanwa BioTech

Day 2

Room S428 4/F

15 DEC 2022

WORKSHOP 3: Intellectual Property

Chair: CHAN Wai-Kit, Partner, The Law Offices of Albert Wai-Kit Chan, PLLC.

Introduction to IP

CHAN Wai-Kit, Partner, The Law Offices of Albert Wai-Kit Chan, PLLC

Biotech Patents – How to Draft an enforceable patent with Limited examples?

15:00-17:00

WONG Pauli, Principal and Chinese Patent Attorney, Eagle IP Limited

Freedom to Operate – why is it important to start early

WONG Alice, Associate, Loeb & Loeb LLP

Evaluation – How to maximize the IP value & Summary

CHAN Wai-Kit, Partner, The Law Offices of Albert Wai-Kit Chan, PLLC

----- Attention -----

Due to demand, Some events were relocated to 4th Floor of Convention Center Room S421 and S428.

Day 3

Main Theatre 5/F

16 DEC 2022

KEYNOTE SESSION 12: Biotechnology in Chinese Medicine Modernization

9:00-9:30

LYU Ai-Ping, Dean of Chinese Medicine, HKBU
Chair: WONG Vivian, Hon President, Hong Kong Association of Integrative Medicine

KEYNOTE SESSION 13: Future Anti-cancer Therapeutics: Put the Cart Before the Horses

9:30-11:30

MAK Tak-Wah, Professor, University of Toronto
Chair: WONG Vivian, Hon President, Hong Kong Association of Integrative Medicine

FORUM 4: China Biotech Services/BGI/Sunrise co-sponsor

10:00-11:00

Topic: China Biotech Services Holdings Roadshow

LAI Chun-Wan, Laboratory Director, AMDL
TAN Wayne, Executive President, China Biotech Services

Topic: Hong Kong Practice in Globalization of Biotech and Development

WU Anthony, Chairman, Sunrise Diagnostic Centre Limited
LIU Albert, General Manager, BGI

Day 3

Main Theatre 5/F

16 DEC 2022

FORUM 5: Capital markets/Investments (Deloitte sponsor)

MC: CHAN Morgan, Student, Chinese University of Hong Kong

Topic: China LSHC Investment Market Overview and Outlook

LAW Kenneth, Deloitte China LSHC Financial Advisory Partner

Topic: Trends, Opportunities, and Outlook for Biotech Investment

Moderator: LAW Philip, Deloitte China SR Venture Capital & Private Equity Lead Partner

Panelists:

11:00-12:30

CHOU Thomas, Co-head Partner of Asia Private Equity Group

SONG Simone, Founder and Senior Partner of ORI Capital

LO Maggie, Deputy Head Innovation and Technology, Invest Hong Kong

SIU Samuel, Executive Director, Morgan Stanley

Topic: Biotech IPO Global Market Outlook

Moderator: CHAN Bong, Deloitte China TMT SR Leader

Panelists:

AU Edward, Southern Region, Deloitte China Managing Partner

FAN Jasmine, Executive Director, Morgan Stanley
Fong Archie, Managing Director and Head of Healthcare, Ping An of China Capital (Hong Kong)

Day 3

Main Theatre 5/F

16 DEC 2022

KEYNOTE SESSION 14: Building a global innovative biopharmaceutical business from Hong Kong and the path forward

14:00-14:30

TO Simon, Executive Director, HUTCHMED
Chair: HU Charles, BIOHK VP, CEO Ryoden Medical Holdings

ROUNDTABLE 8: What's ahead for biotech spending pattern and fund raising strategies (DBS sponsor)

14:30-15:15

Panelists:
HONG Eugene, Executive Director, DBS
JIANG Jasper, Founding Partner, Tiger Jade Capital
LIU Da, Managing Director, CR CP Life Science Fund
SUN Michael, Partner and COO, Lake Bleu Capital
YANG Meng-Yang, Executive Director, CICC

15:20-15:30

Hai Kang Life x Hua Wei Cloud - MOU Signing Ceremony

15:30-18:00

PITCHING Sessions - BIOHK22 Special (Kung-Fu Performance Sponsored by HKTB)

Day 3

Town Hall 5/F

16 DEC 2022

ROUNDTABLE 5: University Knowledge Transfer Offices

Discussion:

- 1. The advantage and possibilities of joint patents, joint licensing, and joint startup companies**
- 2. How to generate synergy among Universities to serve Hong Kong and the GBA and to increase competitiveness in Global market?**
- 3. What would be the view of the Department, Faculty, University, and Government to develop closer collaboration in entrepreneurship?**

10:00-11:00

Moderator:

ZEE Benny, Director, Office of Research and Knowledge Transfer Services, Chinese University of Hong Kong

TAN Alfred, Head of Knowledge Transfer Office, Hong Kong Baptist University

YING Tiffany, University of Hong Kong

KWONG Alex, Head (Biotechnology and Entrepreneurship Support), Office of Knowledge Transfer, Hong Kong University of Science and Technology

HO Johnny, Director (KT), Knowledge Transfer Office, City University of Hong Kong

WONG Kelvin, Deputy Director, Knowledge Transfer and Entrepreneurship Office, Hong Kong Polytechnic University

Day 3

Town Hall 5/F

16 DEC 2022

ROUNDTABLE 6: Digital HealthModerator: CHEN Scarlett

11:00-11:45

Panelists:

PANG Chris, Founder and CEO of ART-QuantYUEN Herman, Director, Curabo Health TechLI Ben, Founder and CEO of Heals Healthcare**ROUNDTABLE 7: Healthcare AI and Big Data Innovations and Opportunities (Basebit sponsor)**Moderator: LIU Andy, President, Basebit Technologies

11:45-12:30

Panelists:

PANG Chee-On, Managing Director, Ally BridgeCHOI Kevin, Business Development Manager, Amazon Web ServicesLO Samuel, General Manager, Nvidia**CityU HK Tech300**

PITCHING Session

14:30-18:00

(invite only*)

2:45pm opening speech

Day 3

SYMPOSIUM 5/F

16 DEC 2022

SYMPOSIUM 4: Rare Disease

Chair: YANG Ling, Managing Director, The Carlyle Group

Topic: **Rising Importance of HK & GBA collaboration on Rare Diseases**

SHAO Eric, Vice President & General Manager, Commercial Solutions, Greater China Commercial Services, IQVIA

Topic: **China Rare Disease 2.0: unlocking the commercial potential of China rare disease market**

XIANG Shawn, CEO, Rarestone Group

10:00-12:00

Topic: **From Molecular Target to Aptamer Drug Discovery towards US-FDA Orphan Drug Designation**

WANG Lu-Yao, Post-Doctoral Research Fellow, Law Siu Dai Institute for Advancing Translational Medicine in Bone & Joint Disease, HKBU

Topic: **The use of patient-reported outcome studies as real-world evidence for rare disease R&D: Vision, application, and challenges**

DONG Dong, Assistant Professor, The Jockey Club School of Public Health and Primary Care (JCSPHPC), The Chinese University of Hong Kong

Topic: **中國罕見病藥物研發與未來發展方向淺析**

CHOW Jason, CFO, Lee's Pharmaceutical Holdings

Day 3

SYMPOSIUM 5/F

16 DEC 2022

SYMPOSIUM 5:

12:00-12:30 **Precision Medicine with Additive Manufacturing
– 3D printed customized products for medical
application**

TSE LF, Chief Medical Director, Koln3D

14:00-14:30

Pitch and fix

Desmond Marshall, Managing Director,
Rouge Ventures

Day 4

Main Theatre 5/F

17 DEC 2022

KEYNOTE SESSION 15: **What do you know about Long COVID?**

Chair: WONG Bing Lou, CSO, Bing Biotech

Topic: **Traditional Chinese Medicine Based Supplement For The Alleviation Of Long COVID Symptoms**

TAM Yun-K. , President & CSO, Sinoveda Canada Inc.

9:00-10:00

Topic: **Development of a Long Covid Treatment Using Artificial Intelligence - Preliminary Experience in Long Covid Sufferers**

LAU Edith, Director, Hong Kong Center for Clinical Research

Product Snapshot : **Fight Covid-19 with K-O-CRON** ,
TSE Shalin 謝寧

FORUM 6: **STEM Education and Biotechnology (STEMLearn)**

Keynote Speaker and Curator: WONG Brian,
Columnist, Hong Kong Economic Journal

Topic: **科技教育、創新引擎及未來生活**

Moderator: WONG Wan-Na, HK01 Chief Journalist

10:00-11:00

QUAT Elizabeth, Member of the Legislative Council,
Chairman of Steering Committee & Founder and

Honorary President of Smart City Consortium
YU Albert , HKBIO Chairman, HKLife Chairman,
BIOHK2022 Co-President

ORR Kevin, Vice President, GBABA Co-Founder,
define CLEAN

Neil Shih, Co-founder of define CLEAN, ISO
9001:2015 Internal Auditor, Committee of Young
Democratic Alliance for the Betterment and
Progress of Hong Kong

CHAN Edward, Chairman, Engineers Without
Borders Hong Kong

Day 4

Main Theatre 5/F

17 DEC 2022

FORUM 7: How to invest in the biotech stockmarket (Morning session)

11:00-12:30

WU Josephine, Chief Investment Officer, Sapere Capital Management Limited

LUI Christopher, Managing Director, Jefferies

NG Andrew, Managing Director and Head of Healthcare, VMS Group

Topic: **To Move with Time - A Big Data Enabled Investment Approach in Healthcare.**

Keynote Speaker: SONG Simone, ORI Capital

SYMPOSIUM 7: Probiotics

14:00-15:00

Topic: **Large-scale clinical study shows CU Medicine (SIM01) microbiome formula reduces risk of infections including COVID-19**

CHAN Francis, Dean, Faculty of Medicine, CUHK

Topic: **Effect of Tea Catechins on Gut Microbiota in High Fat Diet-Induced Obese Mice**

LIU Jian-Hui, Postdoctoral fellow, The Chinese University of Hong Kong

FORUM 12 (GenieBiome sponsor): G-NiiB 用科研重建腸道微生態

15:00-16:00

FAN Rachel, CEO, G-NiiB GenieBiome

分享M3護腸配方用後感

樊亦敏 (TVB Actress), FAN Amy.

以腸道微生態逆轉腸道老化: 腸漏與大腸癌

CHEUNG Wing-Tak, Family Doctor

Day 4

Town Hall 5/F

17 DEC 2022

SYMPOSIUM 6: Smart Hospital are the Future

10:00-11:00 CHEUNG Edward
Senior Systems Manager, Hospital Authority

LAU Stephen
Senior Systems Manager, Hospital Authority

**FORUM 9: When Art and Design meet
Biotechnology**

11:00-12:30 TANG William, Fashion Designer
YOUNG Elaine, Founder, STUDIOPHORIA
JIANG Gina, Managing Director, Hong Kong Institute
of Biotechnology
LEE Edmund, General Manager, Gold Peak
Industries

Day 4

Town Hall 5/F

17 DEC 2022

14:00-15:00

FORUM 11: New direction of biotechnology transition - From BENCH to BOX (Gallant Biotech sponsor)Co-chair: [CHAN Kelvin](#), CHAN GallantTopic: **A mission possible for herbal products, nutraceuticals etc. from Bench to Box & Registration**[CHAN Kelvin](#), Professor, Liverpool John Moores University, UKTopic: **Illustrations of Bench to Box transition on a variety of biotechnology aspects**[CHAN Gallant](#), Founder, Gallant Biotech

15:00-16:00

FORUM 13: Biotech in Hong Kong (Dream Tec sponsor)[CHUNG Christopher](#)

Executive Director and CEO, Dream Tec

[CHEUNG Elman](#)

Business Development Officer, Dream Tec

[FU Elvis](#)

Digital Marketing Officer, Dream Tec

Day 4

SYMPOSIUM 5/F

17 DEC 2022

FORUM 8: Famous Biotech Stories

11:00-12:30

TAN Wayne, Executive President, China Biotech Services

TSUI Joseph, Professor, University of British Columbia


LAM Dominic, Founder of Hong Kong Institute of Biotechnology

One-stop Solutions for Antibody Drug Discovery

1

Gene to Plasmid Services


Express and screen antibodies more quickly and economically.



2

Mutant Library Services

Using different types of precise mutation libraries at different stages can efficiently improve antibody affinity maturation.



3

Mammalian Expression System

GenScript's TurboCHO™ High Throughput platform delivers a range of purified antibody products in quantities from µg to mg in 2 weeks.



SCHEDULE A CALL WITH US

Want to learn more about how we can support your antibody drug discovery and development via a simple but specialized process? Contact us now!



Zhengyang Liu, Sales Manager

Email: zhengyang.liu@genscript.com

Phone: 18225020650

Your One-stop Solution For Gene And Cell Engineering Research

Reliable Services & Products to Make Research Easy



Molecular Biology & Mutant Library

Highly customizable gene, plasmid prep and mutant library solutions for therapeutic target expression engineering



Peptide Synthesis

Advanced technology and comprehensive services for T cell activation, immune profiling, cancer immunotherapy



Protein & Antibody Production

A wide range of expression systems that enable CAR/TCR expression



Custom Antibody Discovery

Full Spectrum of Custom Antibody Discovery Service for profiling and activation of immune cells, lead identification and optimization



CRISPR Services


CRISPR gRNA/Cas9 and HDR donor solutions for precise and efficient genome editing



Viral Vector Packaging

From gene to viral packaging to support knockout screens and viral-based cell engineering

No. B04-05


 D
O
W
N
L
O
A
D

N
O
W

GENE AND CELL THERAPY HANDBOOK

GenScript's viral and non-viral therapeutic total solutions





Tiger Jade Capital

FOCUS ON HEALTHCARE

Established in 2019, Tiger Jade Capital obtained the support and cornerstone investment of China's leading CRO Company TigerMed (300347. SZ, 03347. HK).

Our investment fields include **early and medium-term equity investments** in global medical care fields, such as innovative drug, CROs and medical equipment.

Portfolio Companies



Tiger Jade Capital | 泰欣资本
Healthcare-Focused Private Equity Firm

www.tigerjadecapital.com

19/F Two International Finance Center, 8 Finance Street, Central, Hong Kong

Tel: 852 2251 1826



sirnaomics
Advancing RNAi Therapeutics

應用小核酸技術創製新藥的開拓者

A Leading RNAi Therapeutic Company
with Significant Presence in Both China & USA

創新引領 · 全球視野 · 關注病患

Innovation, Global Vision, Patient-centered

抗腫瘤、纖維化疾病、病毒感染及代謝疾病
多項臨床研究已在中美兩地展開



聖諾醫藥官網



sirnaomics
Advancing RNAi Therapeutics



聖諾醫藥公眾號



聖諾醫藥(美國)
Sirnaomics (USA)

Sirnaomics, 廣州

Sirnaomics, 北京

Sirnaomics, 香港

Sirnaomics, 蘇州

Hong Kong

Where Business Goes to Grow



In Hong Kong, your business has the perfect canvas to connect to all opportunities around the world, against a backdrop of unrivalled advantages:

- Strategic location
- Advanced infrastructure
- World-class talent
- Simple and low tax regime
- Range of financing options
- Convenient access to vast markets in the region

Invest Hong Kong supports your business set up and expansion in our city with free, confidential and customised services.

Get in touch now at investhk.gov.hk

Hong Kong office

Andy Wong, Head of Innovation & Technology
 (852) 3107 1013 ✉ andywong@investhk.gov.hk



Find Us on Social Media





Digital Tech Hub of Hong Kong

Cyberport is committed to nurturing a vibrant tech ecosystem by cultivating talent, promoting entrepreneurship among youth, supporting start-ups on their growth journey, fostering industry development and integrating new and traditional economies by accelerating digital transformation in the public and private sectors.



- Innovative digital community gathered 1800+ start-ups and technology companies
- Focuses on building key clusters of digital tech:

Application



FinTech



Smart Living



Digital
Entertainment
/Esports

Technology



AI & Big Data



Blockchain



Cybersecurity

 Your Springboard to Success


www.cyberport.hk

[f cyberport.hk](https://www.facebook.com/cyberport.hk) [i cyberport.hk](https://www.instagram.com/cyberport.hk) [Hicyperport](https://www.linkedin.com/company/cyberport) [Cyberport Hong Kong](https://www.youtube.com/channel/UCyberport.hk) [@cyberport.hk](https://twitter.com/cyberport.hk)

數碼港
Cyberport

Company Structure of China Biotech Services Holdings Limited

- China Biotech Services Holdings Limited is a company listed on the Hong Kong Stock Exchange GEM board. Stock code: 8037.HK
- Our vision is to become an integrated biotechnology platform dedicated to creating cancer diagnosis, treatment and R&D integration.





DONATE NOW 立即捐款

63

Progress in research is our best chance at defeating cancer. Donate today and help save lives.
推進癌症研究的發展是我們戰勝癌症的最佳途徑。您今天的捐款將幫助拯救生命。



About Us 關於我們

The Asian Fund for Cancer Research Limited (AFCR) is committed to funding cancer research, especially those cancers prevalent in Asian populations, and promoting global collaborations for high impact to save the lives of cancer patients. 亞洲癌症研究基金會有限公司 (AFCR) 致力於資助癌症研究，尤其專注於亞洲人口發病率高的癌症，並通過促進具有重大影響的癌症研究國際合作，救助癌症患者生命。

(852) 2156 9684

contact@afcr.org

www.AFCR.org

Unit 1503, Tower II, Metroplaza
223 Hing Fong Road
Kwai Chung, Hong Kong
香港葵涌興芳路223號
新都會廣場第2座1503室



**ASIAN FUND FOR CANCER
RESEARCH LIMITED**
亞洲癌症研究基金會有限公司

Our Funding Approach 獨特的資助模式

No.A07



Basic Research 基礎研究

We support discovery-oriented research on cancer's underlying mechanisms, genomic pathways, population vulnerabilities, and other important areas. 我們資助以發現為導向的針對癌症的疾病機制、基因組途徑、人口脆弱性和其他重要領域的研究。



Translational Research 轉化研究

We support the translation and development of innovative laboratory breakthroughs into new and more effective cancer treatments, screening methods, and prevention technologies through the impact investment into early-stage oncology companies. 我們通過對早期腫瘤公司的投資，幫助將實驗室的創新突破轉化為新的和更有效的癌症治療、篩查方法和預防技術。



Clinical Research 臨床研究

We fund the build-up of the collaborative and paradigm-shifting clinical platform to accelerate the development of new and effective therapies and technologies. 我們資助建立協作和範式轉換的臨床平台，以加速開發新的有效療法和技術。

Promoting Healthy Living by Advanced Materials & Nanotechnologies

以先進材料及納米技術促進健康生活

Nano and Advanced Materials Institute has established several core platform technologies for the development of marketable products in four main areas: HomeCARE, PersonalCARE, MedicalCARE, and FoodCARE, to support the industry for the development of innovative products.

納米及先進材料研發院 (NAMI) 建立了多項核心平台技術並在四個主要領域：家居護理、個人護理、醫療護理和食品護理，開發可商品化的技術，支持業界推出創新產品。

**Herbal
Wellness &
Plant-based Diet**
草本健康、
植物性飲食



**Tunable Hydrogel
& Healthcare
Nanofiber**
特性可調水凝膠、
醫療保健納米纖維



**Antimicrobial
Technologies**
抗菌技術



**Sustainable
Plastics &
Functional
Elastomers**
可持續塑料、
功能性彈性體



**Probiotics
(Topical and Oral)**
益生菌
(外用及口服)





HK
TECH
300

創科無限·引領未來
Venture Beyond Boundaries



香港城市大學撥出5億港元
首創大型創新創業計劃HK Tech 300

一年多裡，已成功

- 培育超過70間初創公司，各獲高達100萬元HK Tech 300天使投資
- 培育超過360隊初創隊伍，各獲10萬元HK Tech 300種子基金
- 與多間創投公司合作，額外提供天使及風險投資達4億元，支持初創發展

並為青年提供

- 逾100位創業導師及創業培訓
- 共創空間超過20,000平方呎
- 城大研究成果及知識產權
- 工商界網絡聯繫

未來將繼續

為香港創科發展共創新篇章



NASDAQ:GRCL



FIERCE INNOVATION AWARDS

Life Sciences Edition 2022

WINNER
Biotech Innovation
FasTCAR Advantages

FASTER
Availability to patients

ENHANCED
T-cell fitness

SIGNIFICANT
Cost savings



asTCAR

Natural Material
100%(PLA)

天然抗塵蟎
Naturally Dust Mite Suppression

污跡容易清洗
Natural Resistance to Staining

高度透氣，速乾
High Breathability, Quick Dry

天然抑菌
Naturally Bacteriostatic

不易致敏
Hypoallergenic

天然抑臭
Naturally Odor Suppression

天然親膚
Naturally Skin-friendly



PLA 紡織品
Textiles



PLA 無紡布
Nonwovens



No.M13, N11



U.S. Pacific Nonwovens Industry Ltd.
TEL: +852-27246078 FAX: +852-23698779
www.us-pacific.com.hk



68 打造智慧健康灣區 跨境數碼解決方案

No.C02

ONE-STOP SOLUTIONS

THE ONE-STOP EVENT AND SCHEDULE MANAGEMENT PLATFORM
FOR THE USE IN GREATER BAY AREA. PROFESSIONAL, COMPREHENSIVE,
AND EFFICIENT ELECTRONIC CROSS BORDER CHANNEL
FOR DIGITAL HEALTH CREDENTIAL MANAGEMENT.




WWW.CERTIZEN.TECHNOLOGY

02



03



01



**TRUSTED
GBA
ECOSYSTEM**

04



跨境支付
PAYMENT SOLUTION



區塊鏈技術
BLOCK-CHAIN
TECHNOLOGY

電子憑據
DIGITAL RECORD



數碼身份
DIGITAL IDENTITY

電子簽約
CONTRACT SIGNING



電子處方
ELECTRONIC
PRESCRIPTION

NEXT GENERATION Commercialization

The life sciences sector is changing by the minute. That's why we've built the integrated commercial services platform to solve any drug pricing, promotion, access, reimbursement, adherence, or product delivery challenge.

We'll manage the complete launch and commercialization of therapies or address specific program or patient needs. We are EVERSANA.

UNIQUE THERAPIES DESERVE UNIQUE COMMERCIAL SOLUTIONS



Best-in-Class Services for
Established or Emerging Companies



Fit For Purpose Integrated Solutions
to Product or Patient Challenges



Full-Scale Launch or Established
Brand Commercialization Models



EVERSANA®

To learn more, contact Mungo Paterson, Senior Director, Sales & Business Development, EVERSANA APAC at mungo.paterson@eversana.com or APACMarketing@eversana.com.

EVERSANA.COM



Sunrise Diagnostic Centre Limited


華昇診斷中心

不忘初心 · 砥礪前行

Never forget the original intention and forget ahead.




SENTIS™ HPV
自我採樣檢測套裝
SELF-SAMPLING TEST KIT



COLOTECT™
大腸癌自我採樣檢測套裝
Colorectal Cancer Self-sampling Test Kit




華昇診斷中心有限公司
Sunrise Diagnostic Centre Ltd.

(+852) 2818 9690

service@sunrisediagnostic.com.hk

www.sunrisediagnostic.com.hk



DREAM
Tec

夢芋科技

世界首創

重組新冠S蛋白

口服中和抗體加強劑

香港研發
香港製造

攤位位置
L01-02

It's time to
enhance
your health!

增強你的免疫力

Safe &
Effective

安全和有效

專利

PATENTED
PRODUCTS

產品



MiCOVac™ Health Immunity Enhancer

MiCOVac™ 免疫增強劑


2022 Geneva International
Exhibition of Inventions

2022年日內瓦國際發明獎

2022年日內瓦國際創新科技展發明獎

2022年創客中國香港區賽優異獎

8項國際專利發明



香港本地大學研究顯示/指出，服用重組新冠S蛋白後能大大提升細胞免疫因子水平，加強免疫力。

GREEN LIFE TECHNOLOGY PRESENTS

The Tesla Oscillator

Up charge your Cells with High Frequency Energy

Visit us at the

BIOHK2022

14.Dec- 17. Dec. 2022

Booth# Q02

Contact us for demonstration workshop appointments

Marketing@greenlifetechnology.com.hk



OFFICE OF KNOWLEDGE TRANSFER

Email: okt@ust.hk



The Office of Knowledge Transfer (OKT) serves as a bridge between the Hong Kong University of Science and Technology (HKUST) research community and industry to bring University's research output into new products and services. It identifies commercial potential from inventions, formulates intellectual properties (IP) to motivate industry to invest in HKUST technologies, incubates technologies by managing various funding programs, and supports University-Industry Collaboration and start-up companies. It also optimizes translational research opportunities to address industry needs based on HKUST technology and capabilities and thus propel innovation in Hong Kong and beyond.

Through its championing of DeepTech and technopreneurship, HKUST has built a distinctive holistic KT pipeline from lab to market, which has led to a diverse array of start-ups, unicorns, and collaborations with industry, government, and NGOs. A few programs are highlighted below.

EXPRESS LICENSING & TECHNOLOGY ADOPTION PROGRAM (TAP)



The Technology Adoption Program (TAP) aims to encourage HKUST technology adoption with a minimal financial burden on the partnering company. We strive to strengthen the commercialization of HKUST technology for licensing the technology to industry, forming technology start-up companies, industry collaboration or application to funding with industry partnership. Ultimately, HKUST's research outcomes can be translated via TAP and industry partners will be motivated to work with HKUST to create commercial and societal impact.



TECHNOLOGY START-UP SUPPORT SCHEME FOR UNIVERSITIES (TSSSU)

TSSSU is funded by the Innovation and Technology Fund (ITF) and was launched by the Innovation and Technology Commission (ITC), with the following objectives:

- Encourage our students and faculties to start up technology businesses and commercialize their research and development (R&D) results.
- Provide better support for technology start-ups to translate new ideas into business opportunities.



eNano Health Limited

Redefining Health Management

Frequent Testing for Early Awareness

健康管理新理念

恆常自我測試，

趁早預測預防風險

Simple Saliva Test

簡單唾液測試

Diabetes

糖尿病

Stroke/Cardiac Risk

中風風險

Pre-Vaccine Risk

疫苗前風險

Mommy & Baby Health

母嬰健康

Viral Infection

病毒感染

Stress & Nutrition

壓力及營養

Guardian for your whole family

為你的家人把關



www.enanohealth.com



香港臨床研究中心

Hong Kong Center for Clinical Research

Booth K01-02



COMMUNITY BASED CLINICAL TRIALS SITE



- ▶ FDA and EMA audited
研究成果獲得國際監管機構認可
- ▶ 20 + years Experience in Clinical Trials
超過二十年臨床研究的經驗
- ▶ 100 + Global Trials Completed
已完成了一百多個臨床研究計劃
- ▶ 50,000 + Patient in Database
五萬多個志願者的資料庫
- ▶ 10 + Top Recruitment Site
於十多個研究計劃被列為首要招募基地
- ▶ 90% Patient Retention
百分之九十患者成功完成計劃



International
Trials Site

Site
Management
Organization
Services

Scientific
Advisory
Work



Your product is only **ONE STEP** away from unleashing its potential of making tens of thousands of sales and becoming a consumers' daily essential

The ultimate objective of every innovator is to turn their theory into a product in order to truly benefit the public. However, few concepts manage to make it through the whole process successfully while most of them fail to go beyond academic discussion. It is extraordinarily difficult for consumer health products to survive in the market even if it could be productized. Many companies rely on celebrity endorsement as their main marketing strategy. Yet, the cost is high and whether the effect lasts remains questionable.

Max Choice believes "a good concept should not be abandoned, and a good product should not be driven out by the bad". It has motivated us to enter the health product market by acquiring Tinhankin Pharmaceutical Company Limited in 2013. With our experience, Max Choice & Tinhankin repeatedly proved that sophisticated marketing strategies and effective sales channels can together outperform sales driven by celebrity endorsement. Dr. Tam Cordycep Capsule and Lingzhi Capsule series are two that stand out from our many successful cases. With the patented platform pharmaceutical technology (PPT) from our partner in the biotechnology industry, Sinoveda, we can efficiently identify the active

ingredients that provide direct effects, as well as the sites of action of our products. This makes it feasible to obtain the most effective formula and dosage while ensuring a consistent level of active ingredients in every single capsule. Despite the absence of paid endorsement, the aforementioned products have been able to win hearts and minds of customers with real effects and have gained support from numerous returning customers over the last decade.

As the concept of natural health care grows in popularity, herbal health products have emerged to meet the demand. Yet the multi-target mechanism of herbal health products poses a major challenge to maintain consistent efficacy and hence the survival of the products on the market. Max Choice & Tinhankin aim to empower developers of herbal health products by overcoming the difficulties in the active ingredients identification and dosage determination. We strive to turn inconsistent herbs into standardized herbal supplements while providing one-stop service in marketing, retailing, wholesaling and logistics.

If you have an innovative idea or an excellent formula, our biotech partner, Sinoveda, can facilitate commoditization by identifying the active ingredients with its patented platform pharmaceutical technology (PPT).

If you have an existing wonderful product, Max Choice is your bridge to the global market. Max Choice has multiple sales channels all over the world. In Hong Kong, we have 15 retail stores, an online shop as well as a flagship store on HKTVmall. We have also expanded our business across borders by listing on leading e-commerce sites in mainland China, namely Tmall and JD.com, as well as e-commerce platforms in the United States, Australia, New Zealand, and South Korea.

More importantly, Max Choice & Tinhankin can inject confidence into your products! Over the past ten years, we have established an unrivalled reputation as a supplier of consumer health products with real efficacy and rigorous quality control, which is exactly what a new product could ride on. Our experienced team expertizes in consumer and market behavior. We will help your product achieve success in a proven way.

只差一步 你的產品就會是居家必備



助你產品/配方找出成功模式

Booth no. P08

每個發明家的目標是理論最終能變成產品，因為只有商品化才能真正惠給大眾。然而，現實上只有極少數概念能成功轉化，絕大部分往往流於學術層面。儘管有幸商品化，一款保健品要被市場接受，亦是困難重重！當中有企業會視代言人為必然方法，不但代價一點也不輕，且延續性亦存疑。

大棧深信「好概念不應流於學術，好產品不應籍籍無名」，所以於2013年收購天行健醫藥有限公司，踏足保健品領域。大棧•天行健 用自身經歷，反復引證好產品配合成功的市場推廣、暢通的銷售渠道能比代言人效果更出色。眾多成功例子中，就包括大棧的dr.tam蟲草和靈芝膠囊系列，依托伙伴生物科技企業 Sinoveda 的專利藥學平台技術，探研中草藥中的有效活性成份組合及其於人體中的起效之處，從而製成最合適之處方及劑量，並確保每粒膠囊所含的多種活性成份一致。雖然以上保健品從未聘請代言人，依然屹立十載，臨床功效正面，回頭客眾多。

伴隨崇尚天然的保健潮流，草本產品應運而生，但草本產品多靶點的特性，令功效不穩成為產品存留的一大難

關。大棧•天行健總結成功經驗，銳意賦能草本保健品研發者，解決產品定標定量的挑戰，化不穩定的草本植物成為穩定而有效的草本保健品，更為企業提供一站式的市場推廣、零售批發物流服務。

如果你有好意念、好配方，我們的生物科技伙伴 Sinoveda，能通過其專利藥學平台技術，能找出配方中的有效成份組合，助力商品化。

如果你有好產品，大棧是你接通全球市場的橋梁。大棧零售管道多元化，佈局全球，線下15間實體門市，遍及港九新界，線上除了自營網店，亦已進駐HKTVmall，內地電商龍頭天貓及京東，以及美國、澳洲、紐西蘭、韓國等地的電商平台。

更重要的是大棧•天行健能為你的產品注入信心！我們十年來在保健品領域，以真實功效和嚴謹的品質控制，在眾多消費者中建立起的信譽，正正是每款新產品所需要的支持。我們久經鍛鍊的團隊，懂得消費者，熟知市場，以廣受驗證的方式，助你複製大棧•天行健的成功模式。

THE SCIENCE OF HEALING

Pharmaceutical development and consumer health product design

SINOVEDA® RADIATE ANEW

Booth no. P09

Plant based supplements in Hong Kong come and go at a rapid rate. Only 3% of new products survive the market on an annual basis. Quality and efficacy fluctuations are the major reasons for attrition. Not only can Sinoveda Canada Inc. circumvent these hurdles, it uses its technology to enhance quality and consistency of products.

Plant-based medicine including Traditional Chinese Medicine have never received the recognition it deserves. Quality, consistency, and lack of knowledge of active substances are key problems.

Sinoveda Canada Inc. was founded to bridge the quality gap of plant-based medicine. Through its patented Pharmaceutical Platform Technology (PPT), active molecules and their mutual synergistic interactions are identified. With an appropriate design of dosage forms, product quality and effectiveness are ensured. This process of developing plant-based products opens an avenue for these products to ascend to new height.

The mission of Sinoveda Canada Inc. is to help plant-based product developer to shorten development time from years to months, and from low to premium qualities.

Founded in 2006 by two pharmaceutical scientists, Drs. Yun K. Tam and Nuzhat Tam-Zaman have a combined experience of more than 50 years in pharmaceutical and consumer health product development. Sinoveda Canada Inc.'s vision is to develop plant-based medicines that are effective, safe, and affordable. The company is built on a patented platform pharmaceutical technology (PPT). Recently, artificial intelligence has been incorporated into PPT to efficiently develop recipes of pharmaceuticals and consumer health products. PPT has been successfully used to develop a drug candidate for treating postmenopausal symptoms and 14

“To develop plant-based medicines that are effective, safe, affordable and beneficial”



consumer health products that are on the Hong Kong, China (cross border e-commerce), Canada, USA, and Bangladesh markets.

At the beginning of 2022, Sinoveda Canada Inc. has secured investment to develop cannabis derived liver and colon cancer treatments. The goal is to advance combination candidates that are safe and could counter key cancer targets which are essential for eradication. In a third-party in vitro proof of concept study, two candidates have been shown to be effective in xenografts obtained from liver cancer patients. The company is preparing the in vivo proof of concept and clinical study. On the consumer health product front, recipes for age related health issues such as alopecia, long COVID and heart and blood sugar support are being developed. Initial results are promising.

A Proven Drug Discovery Platform

Multiple compound-multiple target drug discovery paradigm

Biological and chemical data mining

Bioactives Identification

Data driven/AI

以科學拯救生命

「市面上充斥各種草本保健品，但只有3%能存留超過一年！失敗主因源於功效不穩定，Sinoveda Canada Inc. 除讓你突破這個挑戰外更能進一步提升你的產品功效」

草本保健品以至中醫藥之所以不能成為標準化藥物，關鍵是受限於草本藥材的質量差異，藥效不一致，以及對活性成份和劑量的不確定性。

Sinoveda Canada Inc. 的成立正是為回應這方面的市場需求，通過自研的專利藥學平台技術 (PPT)，找出草本藥物中發揮效用的活性分子組合，並以此開發出可確保療效的配方，從而研發出有效、安全和可負擔的草本藥物，為中醫藥的發展局限，提供新路向。

Sinoveda Canada Inc. 願景是助力每位草本產品研發者，將以往以年計的研究時間，縮短至以月計，加快找出配方中的有效成份及其黃金比例，從而降低開發成本，增加商品化的成功率。

Sinoveda Canada Inc. 是一家位於加拿大埃德蒙頓 (Edmonton) 的生物科技企業，由兩位擁有超過50年經驗的藥物學家 Dr. Yun K. Tam (譚潤球博士) 及 Dr. Nuzhat Tam-Zaman (譚紐莎博士) 於 2006年合作成立。近年公司的專利藥學平台技術 (PPT) 結合了人工智能技術，不單可應用於提升藥物和保健品的功效，更能加快其研發的速度。其中一個藥物研發的成功例子是治療更年期後症狀的候選藥物。另有14款面向消費市場的高效保健產品，並已於中國香港 (含跨境電商)、加拿大、美國和孟加拉市場銷售。

Sinoveda Canada Inc. 於 2022 年年初更獲資金支持研發新一代大麻衍生針對肝癌及大腸癌的抗癌藥物，研發目標是推出高效低副作用的多靶點標靶藥。近日，兩候選藥物經由第三方實驗室使用新型人類肝癌癌模型測試，實驗呈現正面結果，公司因此正籌備開展下階段動物實驗和臨床工作。此外，公司亦正利用自研平台發展多款草本藥物，用以治療新冠後遺症、圓禿、心臟疾病、糖尿病和老化相關疾病等。截至目前，已獲初步候選配方。

parexel®

HEALTH ADVANCES

Strategy Consultants for the Healthcare Industry

Keeping patients at the heart of everything we do!

Your trusted partner in China for 23 years

With Heart™



WORLD'S FIRST ANTIVIRAL 3D PRINTING MATERIALS

全球首創防病毒三維打印物料

IMU+ IMMUNE
MATERIALS

No. C06



- 99.9% 殺滅 COVID-19 及常見細菌
- 無懼磨損 | 效力超過 3 年
- 可與其他塑料混合

Products developed with
IMU+™ materials
使用 IMU+™ 物料製造的產品



醫院管理局
HOSPITAL
AUTHORITY

Authorised Vendor for HA
醫院管理局認可的供應商



+852 9686 0418



info@immunematerials.com



www.immunematerials.com





@HKDTECH



No.M04

HK-Dtech is a startup specializing in the field of **In-Vitro Diagnostics (IVD) and Life Sciences**. The company develops and produces high-performance fluorescent nanoparticles with unique characteristics to improve the detection of biomarkers in the service of scientific research and medical diagnosis, offering higher detection sensitivity with user-friendly protocols applicable to various molecular and cellular biology techniques.

BRIGHT-DTECH™

This patented technology based on lanthanide nanoparticles offers exceptional performance in a wide range of fluorescent analysis applications. We increase the performance of current fluorescent markers with our nanoparticles in different applications (Immunoassays, cell imaging, flow cytometry, lateral flow, dot Blot, TR-FRET).

Bright-Dtech™ (BDT) has unique characteristics:

- High brightness
- Multi-detection, several colors of nanoparticles available
- Long emission Lifetime (TRF - Background Noise Suppressed in Sample)
- High stability
- No toxicity
- Distinct spectral signature – Unique and recognizable emission spectrum
- Coupled with different biological entities (IgG, Streptavidin, Biotin...)

LINK-DTECH™

Link-Dtech™ range is made up of conjugation kits that make it easy to perform binding reactions without having access to specialized chemistry capabilities.

The kits are designed to be robust and universally adaptable to any type of given analyte, antibody, and other biological products.

全球首创国产 全柔性微型内镜手术机器人

AGILIS ROBOTICS

主要市场



消化道

- ESD (内窥镜粘膜下剥离术)



膀胱肿瘤

- ERBT (膀胱肿瘤整块切除)

技术优势

全球首创国产

全柔性微型内镜手术机器人



❖ 无缝集成现成内镜

- <2.8mm内径
- 直接穿过现成内镜工具通道

❖ 更细小，更易操控

- 笔型控制器，快速于机械臂控制及内镜操作间切换
- 操作椅流动性高，兼顾手术操控和照顾病人

AI驱动手术引导

- 以内镜影像进行工具位置测估，辅助用户训练

公司背景

Agilis Robotics 是孵化于香港大学的一家衍生公司，现致力于开发用于内镜手术的柔性机器人设备。我们的机器人系统与当前临床中使用的传统内窥镜直接兼容，让医生在沿用已经熟悉的临床工作流程的前提下，可以实现更灵巧的机器人化操作和更高的精准度。我们的专利技术可广泛应用于从柔性 and 刚性内镜到腹腔镜手术等多类手术领域中。



- ❖ 5 活动自由度 / 机械臂
- ❖ 更灵活的工具操控和组织抓取
- ❖ 多款机械臂工具，
应付不同手术需要



电邮联络



网页查询

BUILDING BRIDGES

ADVANCING INNOVATION

PROVIDING WINGS TO SOAR



EAGLE IP

鷹翅知產有限公司

Hong Kong Shenzhen Macau

Experts in IP protection

- Patent experts with significant biomed / pharma industry experience
- Strategic approach to building strong global IP portfolios that last
- Top-notch team of life science US and Chinese patent agents / attorneys

 eip@eipgroup.asia

 www.eipgroup.asia



WeChat



Email



Blog



PHARMA.AI

Artificial Intelligence for every Step of Pharmaceutical Research and Development

PandaOmics

Broaden data analysis & visualization horizons

- Decipher & analyze any published OMICs data
- Discover and evaluate novel drug targets
- Uncover novel strategies for drug repurposing

Chemistry42


Explore uncharted chemical space

- An automated end-to-end machine learning platform
- Novel & diverse molecules for targets of interest
- Structure and ligand-based drug design strategies

inClinico

Design & predict clinical trial outcomes

- Predict success rates of clinical trials
- Identify weak areas in trial design early
- Adopt best practices guided by InClinico



**Insilico
Medicine**





K-O-CRON

SUPER GOLD
PLATINUM + HERBAL
ANTIBACTERIAL
SANITIZER

鉑金草本抗菌消毒液

持續殺菌6小時

不含酒精及次氯酸等成份



成份：

紅花、連翹、桃仁、菊花、紫蘇、桔梗、八角、木香、藿香、
 倉朮、白朮、青皮、花椒、丁香、薄荷、大馬士革玫瑰、
 富硒米、鉑金離子

中醫推介草本配方用科技萃取而成

採用各種精選草本植物，以現代化科技利用鉑金等微量元素催化萃取而成，可直接噴於皮膚、衣服、餐具及各種家居用品。產品同時含大馬士革玫瑰，有保濕的作用，對於皮膚乾燥、痕癢或紅腫有舒緩的效果；而鉑金離子能殺細菌、真菌和病毒，在健康衛生方面帶來保障。

通過以下抗菌測試

- 青春痘菌
- 大腸桿菌
- 退伍軍人桿菌
- 金黃葡萄球菌
- 木黴菌(真菌)

並完成以下安全測試

- 重金屬及有毒元素測試
- 微生物限度測試
- 有機氯類殘留農藥測試



www.k-o-cron.com



Patent



Trade Mark



Design



Copyright

Professionally Qualified IP Attorneys

Local Insights for Global IP Strategy

Competitive Rates Personalised Services

INCOMPASS IP LIMITED comprises a team of attorneys based in our Hong Kong and London offices since 2012. Our attorneys are registered and practicing in a diverse range of jurisdictions, including Hong Kong, China, Europe, UK, Australia and New Zealand. We provide international IP services directly to local clients at competitive rates based on your specific needs.

We are an award-winning firm with attorneys who have been recognized as world-leading practitioners. Our elite clients include a number of reputed universities and research institutes in Hong Kong, as well as various local and international clients ranged from small businesses, start-ups to multinational companies.

Special offers :

- Free initial consultation
- Free initial patent search
- Free initial trade mark search

We can help you with:

- ❖ Original drafting of patent specifications
- ❖ Filing and prosecuting trade mark and patent (invention, utility model, and design) applications
- ❖ Patentability and infringement searches and opinions
- ❖ Trade mark searches
- ❖ Portfolio management
- ❖ Enforcement and litigation support
- ❖ IP strategy
- ❖ IP transactions such as licensing-out, licensing-in, sale, and acquisition
- ❖ Initial and closing due diligence
- ❖ Intellectual capital auditing and management
- ❖ Training and education
- ❖ Unregistered rights, technical know-how, confidential information, trade secret
- ❖ And other advisory, drafting, filing, registration, enforcement, and commercialization services



大灣區實驗服務平台

Greater Bay Experimental Service Platform

生命科學儀器辦公室管理平臺

Regional Office Management Platform

科學儀器 Scientific Instrument

GMP制藥機械 Pharmaceutical Machinery

科研推廣 Research Technology Promotion

儀器開發 Equipment Launching

實驗服務 Experimental Service

國產機械出口計劃

OEM Machinery Export Scheme

Booth #C07

Bioprobes Ltd.

Bioprobes Life Science & Technology Service Ltd.



拜譜有限公司

www.bioprobeshk.com
www.bioprobeshina.com



Wechat search

拜譜科學儀器

TEL: (852) 2773 9888
(86-020) 8735 7737



香港新一代文化協會是一間教育培訓機構，亦是政府認可的公共性質慈善機構，創立於1974年。

我們一直秉承創會宗旨，以「視野、創新、博識、承擔」作為培育人才的目標，致力為前線教師及青年學生提供最適切的活動和服務，工作範疇包括：科普創意、STEM教育、通識教育、國情教育、教師支援、創新創業、領袖培訓等。



第9屆

香港大學生創新及創業大賽

報名詳情



創新及創業中心

截止報名：**31/3/2023**

參賽範疇

- 生命科學
- 數理/機械
- 資訊技術
- 能源環境化工

- 創業計劃
- 初創企業
- 社企/文創



獎金
 銜接大灣區及全國賽事
 直入香港科學園 ideation program

報名詳情



科學創意中心

第25屆

香港青少年科技創新大賽

- 參賽範疇
- 研究及發明(小學/中學組) - 包括生物及健康類
 - 科學幻想畫
 - 科幻小說
 - STEM活動
 - STEM學校
 - STEM教師
 - STEM教具

截止報名：**18/1/2023**



獎盃
 獎金(專項獎)
 晉級全國及國際賽事





Shenzhen KangTi Life Technology Co., Ltd

About Us


AlpaLife is a biotechnology company in China founded by scientists specialized in nanobody discovery & production and G-protein coupled receptors (GPCRs) related drug discovery. We offer one-stop solution from antigen preparation to selected nanobody purification and evolution. With extensive experience in custom single domain antibody development, we are ready to help simplify and accelerate your research by novel nanobodies.

"Team of PhDs. to meet the interest of global scientific community."



2000m² Laboratory

Nanobody Discovery workflow



AlpaLife has provided nanobody CRO solutions for antigens and target proteins including but not limited to Hpv16, Hpv18, Claudin 18.2, Lirb-2, Amyloid A, Procalcitonin, TAC2, PD-1, PD-L1, CTLA4, CD3 (epsilon & gamma), Integrin, virus-like particles, IL-5, PCSK9, KLH coupled peptides and tags (HA, Myc, Flag V5), GST, CD3, CD7, CD19, CD20, CD22, CD28, CD33, CD38, CD70, CD73, CD79, CD123, CD167, GRP78, Human RAGE, HSP70, HSP90, ROR1, IG F2R, IGF1R, GPC3, SARS-CoV-2 S1, EBV gH/gL, KRAS, CXCL1, GUCY2C, HT PXL2, Nectin4, human apolipoprotein A-1, human apolipoprotein B, human hemoglobin, SERPINA3, human transferrin, GFP, mCherry, mouse IgG, rabbit IgG and antigens provided by our customers without annotation.



Selected Global Clients



Contact Us:
Web: www.alpa-life.com
Email: info@alpa-life.com
Tel: + (332) 248-9591
LinkedIn/Facebook: AlpaLife
Whatsapp: 17077601385




Comprehensive CRO services on G protein-coupled receptors and other membrane proteins



"Drug Discovery Engine in 21st century" - Nature Reviews Drug Discovery, 2017

Trends in pharmacological sciences, 2013




- What we offer?
- High active and pure GPCR preparation;
- Structural determination of GPCRs;
- Functional characterizations of GPCRs;
- Nanobody development against GPCRs
- And more..



三和生物科技有限公司 Sanwa BioTech Limited

ALiA – 新一代即時診斷平台
ALiA – Next Generation Diagnostic Platform

- 15分鐘內提供多種診斷結果
- 可辨別長者群體中最常見及致命感染，如流感病毒、合胞病毒、肺炎鏈球菌、新型冠狀病毒
- 為專業人士及護理人員提供即場準確診斷
- Deliver multiple diagnostic results in 15 minutes
- Identify the most common infections in elderlies (e.g. Influenza, RSV, Streptococcus and COVID-19)
- Provide healthcare professionals and nursing staffs with on-the-spot diagnosis



聯絡資料

Contact Information



Visit Our Website



Follow Our LinkedIn

☎ 2698 6612

✉ Inquiry@sanwabiotech.com





一站式企业服务

多元配套 一步到位

企业方案

-  物业咨询转介
-  企业保险
-  高管人才安排
-  融资策略

专才配套规划

-  签证申请服务转介
-  安家服务
-  来港升学服务转介
-  医疗配套



(852) 2809 3838



enquiry@midlandwealth.com



www.midlandfinancial.com.hk



香港旺角亚皆老街33号美联金融大厦14楼



精明知識產權策略 業務升級增值秘訣

免費知識產權諮詢服務



- ▶ 香港律師會的執業律師（顧問）提供一對一諮詢面談服務
- ▶ 協助香港中小企業加深對知識產權（IP）的認識，制訂有效的知識產權管理及商品化策略

諮詢範圍涵蓋：



IP註冊



IP管理



IP授權



IP盡職審查

立即申請：www.ip.gov.hk/ipcs



知識產權培訓課程

增加專業知識和技能，全面提升管理企業知識產權的能力

基本課程

- ▶ 知識產權基礎課程
- ▶ 內地的知識產權管理與保護
- ▶ 香港的知識產權註冊及申請程序
- ▶ 企業保護商業秘密的策略與方法
- ▶ 專利基礎課程



IP保護



IP註冊



IP管理



IP策略

進階課程

- ▶ 知識產權審核及盡職審查
- ▶ 專利商品化管理及策略
- ▶ 技術轉移管理及策略
- ▶ 知識產權管理人員實務工作坊

課程概覽及報名：www.ip.gov.hk/ipmtp



知識產權管理人員計劃

- ▶ 協助香港企業（特別是中小企業）建立知識產權方面的人力資源，把握知識產權貿易所帶來的機遇
- ▶ 提供內容深入的知識產權培訓課程，讓企業的知識產權管理人員更有系統地增加專業知識和技能
- ▶ 所有在香港註冊的企業均可免費參加

為何參加？



優先報讀培訓課程



尊享培訓優惠



獲發參加證書



掌握最新IP資訊

更多：

- ▶ 免費參加知識產權管理人員實務工作坊及獲贈實務指南
- ▶ 以特價參加「亞洲知識產權營商論壇」

費用全免 立即登記

www.ip.gov.hk/ipms



瀏覽 www.ip.gov.hk
了解最新的知識產權貿易支援服務及資訊

查詢熱線：2961 6833



知識產權署



About Beth

Beth Bioinformatics Co. Ltd (Bethbio) is a Hong Kong Science and Technology Park IncuBio company, and also a member of the Hong Kong Artificial Intelligence Laboratory (HKAI Lab). Originated from frontier research of the Chinese University of Hong Kong, Bethbio translates the cutting edge technologies to application. Bethbio has reached co-development agreements with a number of vaccine manufacturers to provide biological information technology support in vaccine design and development.



◆ Vaccine effectiveness prediction

The technology developed by research team of Bethbio and the Chinese University of Hong Kong achieved rapid *in silico* VE evaluation by virus genome information. VE of a given period and region against a specific variant or for a particular cohort can be estimated.



◆ Vaccine antigen design

Through analyzing the complete genome and mutation pattern of virus, Bethbio can accurately predict vaccine strains and design vaccine antigens most suitable for the target area. Beth holds the independent intellectual property rights of the framework, which can be used for influenza, CoVID-19 and other viruses.



◆ Codon optimization and de-optimization

Bethbio used computational biology to comprehensively consider the sequence structure and the codon usage bias, and developed a new framework to provide the most effective vaccine optimization design for different expression systems and vaccine production platforms.



◆ Early screening of human complex disease

Through the analysis of the third-generation gene sequencing results, Bethbio successfully transformed genome data analysis into clinically meaningful interpretation. The algorithm achieves any diseases prediction by human genome data (e.g. Alzheimer's diseases, schizophrenia) stably and accurately without parameter tuning.

滬港中科國際生物科技有限公司 ZSHK Laboratories Limited

滬港中科國際生物科技有限公司（ZSHK LABORATORIES LIMITED）是一家生物醫藥臨床前研發服務公司，以藥物與醫療器械臨床前研究評價服務為主營業務，為全球的醫藥企業和研發機構提供包含藥理藥效研究、藥物代謝動力學研究和安全性評價研究等服務的一站式研發服務平臺。滬港中科分別在香港科學園、廣東省深圳市坪山區、江蘇省蘇州市蘇州工業園區三地建有獨立實驗室。滬港中科積極布局供應鏈建設，已布局湖南實驗犬繁育及科研基地和廣西非人靈長類動物繁育及科研基地。

ZSHK Laboratories Limited is a biopharmaceutical pre-clinical research and development service company mainly engaged in pre-clinical research and evaluation services for drugs and medical devices. A one-stop evaluation and research service platform, it provides services including pharmacology, pharmacodynamics, pharmacokinetics, toxicology and other safety-related studies for pharmaceutical developers and researchers worldwide. ZSHK has established independent laboratories in Hong Kong Science and Technology Park, Pingshan District of Shenzhen, Guangdong Province, and Suzhou Industrial Park of Suzhou, Jiangsu Province. Paying active efforts in supply chain deploying, ZSHK has established breeding and research bases of experimental dogs and non-human primates in Hunan and Guangxi.

香港檢測 · 香港認證

TESTED IN HONG KONG

CERTIFIED IN HONG KONG

 香港檢測和認證局
The Hong Kong Council for
Testing and Certification
www.hkctc.gov.hk



高度專業誠信
High Professional Integrity

完善的知識產權保障
Good Intellectual Property Protection

卓越技術水平
High Technical Competence

敏銳的市場觸覺
Quick Response to Market Needs

健全的認可制度，廣獲國際承認
Robust Accreditation System
Being Highly Regarded Internationally

作為自由港、擁有先進的物流支援
A Free Port with Excellent Logistics Support



使用獲香港認可處認可的機構所提供的檢測認證服務，可提高顧客對你的產品和服務的信心。

Using testing, certification and inspection services provided by Hong Kong Accreditation Service's accredited organisations could enhance customers' confidence in your products and services.



想找合適的獲認可機構，請瀏覽香港認可處網站：
To find a suitable accredited organisation, please visit the
website of Hong Kong Accreditation Service:

www.hkas.gov.hk



Cell-Free DNA Storage Tube

Preservation of cfDNA with a specially formulated solution that prevents cell lysis

Safety and durability through polyethylene terephthalate (PET) and glass material

Product Highlights



Specimen stability

- Prevents blood coagulation with K_2 EDTA
- Preservation of nucleated cells, cfDNA and ctDNA
- cfDNA, gDNA and ctDNA in whole blood samples can be preserved up to 14 days at 6 °C -37°C.

Safety and durability

- Manufactured in accordance with ISO 9001 & ISO 13485
- Shelf life (unfilled tube): 18months

Convenient

- Preloaded with negative pressure & specially formulated preservation
- Ideal sampling tool for collection, stabilization and transporting cfDNA in whole blood sample
- Optimize the sample quality for subsequent NIPT, tumor screening NGS applications

中道養生醫術 道家文化

本會為非牟利團體，創立於二零零三年「沙士」橫行之時。創會會長陳讓珠博士以我中華道家醫術精髓，幫助不少「沙士」病人得以康復。在眾多病患一致請求下，一群善長、義工及病患出錢出力，中道養生醫術學會應道而生。

本會旨在交流中醫學術及道家文化，並有註冊中醫於每周六為會員提供義診服務，此外也會不定期舉辦中醫養生保健及道家文化的相關講座。



中道養生醫術學會
Taoist Culture of Healthy Living Association

地址：荔枝角瓊林街111號擎天廣場22樓D01室
電話：3594 5762

參與義診中醫師資料

袁智勇醫師 註冊編號006819

陳穎芯醫師 註冊編號009277

機構：中道養生醫術學會 / 優悅中醫中心

地址：荔枝角 瓊林街111號
擎天廣場22樓D01室

電話：3594 5762

區梓桓醫師 註冊編號006804

機構：和宜中醫診所

地址：新界葵涌和宜合道198號
誼發大廈地下33號舖

電話：9848 9817



HKG epi THERAPEUTICS Ltd.
Harnessing the epigenome

Booth number : B08

成立於2016年，創辦人Dr. Moshe Szyf及團隊有接近40年研究有關人類表觀遺傳學的經驗，致力研究癌症獨有的「甲基化」表觀基因特徵。每一種癌症都具有獨特的甲基化指紋圖譜，有效提早顯示癌症概率，擔當在癌症檢測領導角色。



泛癌 33種癌症早期精準檢測

+852 5282 5780

香港新界沙田科學園科技大道西11號
生物科技中心二座3樓313-315室

總代理 : Amazing Flair Ltd

WWW.HKGEPI.COM.HK

BGI

世界基因行業的奠基者
和引領者之一

基因科技造福人類



@BGI Genomics

No.N01



COLLEGE of AMERICAN
PATHOLOGISTS
Laboratory Quality Solutions

The Global Leader for Laboratory Excellence



**Fostering excellence
in laboratory medicine
worldwide—over 23,000
laboratories in more than
115 countries.**

- College of American Pathologists (CAP) accreditation enables operational excellence in laboratory practices for 8,000+ laboratories in 55+ countries.
- Our 700+ proficiency testing/external quality assessment (PT/EQA) programs cover a comprehensive range across clinical and anatomic pathology testing needs.
- Additional improvement programs and management tools further support quality goals and business objectives.

With more than 75 years of expertise, the CAP can help you achieve your laboratory quality initiatives, reaching a higher standard of care for patients.

Visit the **CAP booth B09** at BIOHK2022, or contact us at international@cap.org to learn more.




安捷伦为您提供全套创新解决方案


支持客户广泛的应用需求

安捷伦科技是生命科学、诊断和应用化学市场领域的领导者，公司为全世界的实验室提供包括仪器、色谱柱、数据库、方法等在内的整套解决方案，助您从容应对复杂的分析挑战。

如今，致力于生物药物开发的科学家能够利用安捷伦简便易行的完整解决方案进行生物药物相关表征。安捷伦提供开放式解决方案使科学家们能够在安捷伦硬件平台和软件平台上轻松运行样品，用户还可轻松执行复杂的应用，如完整分子量分析、序列覆盖率确认和 PTM 分析和糖型分析等。

安捷伦服务于整个生物制药产业价值链，提供直接满足客户需求的完整解决方案





Full-Spectrum Bio LC

BIO

New Agilent InfinityLab Bio LC Solutions

As biopharma analysis becomes increasingly complex, you need resources that let you meet a wide array of challenges. The Agilent InfinityLab Bio LC Solutions include a complete, innovative range of fully biocompatible and bio-inert LC systems that help you expand your bioanalysis capabilities. You can complement these systems with bio columns, MS detection, software, and service options to create a comprehensive solution that spans all your bioanalysis needs.

www.agilent.com/chem/complete-bio-lc




Pioneering DNA Vaccine

WE CARE • WE CURE • WE PREVENT

Immuno Cure BioTech Group is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of novel immunotherapies for cancers, inflammatory and infectious diseases based on its **patented PD-1-enhanced DNA vaccine** and **Anti-Δ42PD1 Blocking Antibody** Immune Blocking technology platforms; with **2 vaccine candidates in clinical trials**.

Advantages of PD-1-Enhanced DNA Vaccine



艾丝为克
ICVAX

Clinical Trial
Phase 1
Q4 2022 – Q1 2023

埃斯克福
ICCOV

Clinical Trial
Phase 2
Q4 2022 – Q1 2023



www.immunocure.hk

Hong Kong · Shenzhen · Beijing · Shanghai

TRONEX

HONG KONG

**Advanced Product Quality
and Clinical Performance**

**Experienced and Efficient
Program Management & Support**

**Highly Resilient & Diversified
Global Manufacturing Supply Chain**

*Award-Winning Supplier
with Over Three Decades
of Trusted Performance*



SenseTime

A leading global AI software company

committed to creating a better AI-empowered future through innovation

3,500+

R&D
Employees

250+

PhDs and PhD
Candidates

40

Professors

52

Top-tier University
Collaborations

15

Joint Labs
Globally

SenseTime Group Inc stock code **0020.HK**

successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited (HKEX)




SenseTime's healthcare team

is comprised of top industry talents and has published dozens of articles in leading journals and conference proceeding. The team empowers our partners with leading AI products.

In the area of drug discovery, the team's research results have been accepted by prestigious journals including Nature Precision Oncology, Nature Machine Intelligence, Lancet Digital Health etc and focus on the whole process of drug development from drug discovery, preclinical research, clinical research to go-to-market.



紮根於香港，是唯一一家總部位於中國且在包括日本、歐洲和美國在內的所有主要海外PCI球囊市場中位列前六的PCI球囊製造商。



BIOHK 2022
香港國際生物科技展

12月14至17日

歡迎各界朋友親臨觀展

展位:K12-14



最強人氣保健飲品品牌

針對疫情研發 有助紓緩長新冠 草本小分子「泡」出全方位保護

在過去兩年多，全球備受新冠疫情困擾，大眾對健康的關注度亦因此創出新高，包括怎樣增強免疫力以防感染、一旦確診需要怎樣治療，但即使康復後，亦有可能要面對長新冠後遺症等。新冠疫情即將進入第四個年頭，很多國家已經通關及解除口罩令，但大家亦不能掉以輕心。在眾多保健飲品中脫穎而出的冠樂福，正正是針對新冠疫情而研發，成分天然、效用顯著，自推出市場後，已累積了不少口碑及人氣。

科技含量極高 集預防、紓緩、調理於一身

冠樂福的成功取決於兩大因素：其一是它的市場定位；其二是它的科技含量。母公司嘉倫生物科技股份有限公司行政總裁兼首席科學家陳嘉倫博士表示，冠樂福西柚泡騰片的誕生是為了解決新冠疫情的情況，公司將產品定位於針對新冠肺炎研究的標靶式健康飲品，有別於一般傳統強身健體的產品，提供了具專屬性的細胞保護。而在科技層面上，採用天然草本配方，不含西藥成分，以草本小分子作為基本生物活性成分，有助阻隔病毒入侵人體細胞。即使不幸染疫，產品亦能透過降低3CL蛋白酶的活性從而減輕及紓緩症狀，其中的活性成分更可以重新激活腦細胞，改善康復者最害怕的長新冠後遺症。

性價比高 為新冠疫情提供健康屏障

冠樂福的售價亦十分親民，每杯平均不到港幣十元，這亦是能夠吸引消費者的主要原因之一。此外，冠樂福以分子包裹技術工藝，把苦味極重的藥效分子包裹著，在抵達胃部時才釋放出來，再配以甘草及羅漢果的天然調味劑，無需加糖，都能提升口感，更加易於飲用。



陳嘉倫表示，面對疫情複雜多變，在人類與微生物世界的角力關係中，冠樂福擁有低開發成本、靈活多變及具靶點專業性的優勢，未來亦會繼續開發不同口味，以及研發針對不同病毒如流感等的新產品，希望能夠幫助社會回到疫前的正常生活模式。

**Crowns
OFF
冠樂福**

冠樂福是嘉倫生物科技 GALLANT BIOTECH 旗下4個品牌的其中之一，其餘品牌還包括「豬博士」美容護膚系列，以及將於明年推出的「雅歌」天然精油系列、「淡泉清」環保產品系列。

人氣之選



草本小分子 全面對抗變種病毒

冠樂福西柚泡騰片以草本小分子作為基本生物活性成分，即使變種後的新冠病毒把它們呈現皇冠狀的刺蛋白收藏起來，產品的草本小分子也能接觸到新冠病毒刺蛋白位點，並將體內病毒消滅，令冠樂福能夠成為對抗新冠的抗疫新星。

冠樂福
Crowns OFF

網址：www.gallantbiotech.com

INFO



CaTAGene

新冠病毒病核酸檢測

COVID-19 RT-PCR testing

全自動微生物樣本處理系統
Automatic Microbial Sample
Processing System

- ✓ 政府認可醫療檢測機構
HK SAR-Recognised Testing Institutions
- ✓ HOKLAS ISO 15189:2012 認可實驗室
HOKLAS ISO 15189:2012 Accredited Laboratory
- 提供政府認可，快捷及準確新冠核酸檢測服務
- ✓ Speedy and Accurate Result -
Government Recognised COVID-19 PCR Test Service

(852) 9490 4883


✉ info@catagene.com.hk

(852) 2690 9693

🌐 www.catageneshop.com.hk

 **CaTAGene**

Powered by CMA Testing



女性恩物，比閨蜜更閨蜜

生物科技創未來
健康生活自然來



Alpha Hygienic



alphahygienic



Alpha Hygienic



觀塘成業街19-21號成業工業大廈5樓01室

YOUNG⁺
WELLNESS
尚醫健康

DNA WeCheck
天資基因檢測中心

關注我們

即送檢測服務 最高價值
HK\$3,280



體重管理
基因檢測

OR



骨質密度
超聲波檢測

OR



sEMG肌電脊骨
壓力檢測

OR



身體成份分析

OR



心血管硬化
程度檢測

五選一禮品，展會期間每日名額100位



立即掃碼登記

香港國際生物科技展2022
14/12/2022 - 17/12/2022

展位L13、L14
歡迎參觀或查詢

Find Us @



youngplus.com.hk

尚醫健康體檢中心

☎ 2158-2198

☎ 9601-9138



銅鑼灣 銅鑼灣羅素街2-4號2000年廣場21樓全層(時代廣場對面)



荔枝角 荔枝角長沙灣道910號安泰大廈12樓全層(港鐵荔枝角站C出口)

Centre for Novostics aims to push the frontiers in molecular diagnostics based on cell-free nucleic acids in blood.

Please visit our booth at M03 for more information.



TAKE2 PROPHECY™ 早期鼻咽癌篩查

Early Detection Test for
Nasopharyngeal Cancer (NPC)

篩查特點：
Test Feature Highlights:

- 採用次世代DNA測序技術
Utilising Next-generation Sequencing technology
- 針對帶有鼻咽癌特徵DNA作檢測
Capturing the NPC-associated DNA signal in the bloodstream
- 準確度 >97%^{1,2}; 及假陽性率極低(0.7%)²
Achieving sensitivity >97%^{1,2} with remarkably low false-positive rate (0.7%)²
- 源自中大頂尖基因研究團隊, 經萬人臨床實證¹
Originating from CUHK's world-class research team and has been validated in a large-scale clinical study¹
- 有效識別早期無徵狀患者
Effectively identifying early-stage NPC patients from asymptomatic individuals

張達明「鼻咽癌康復者」

早期鼻咽癌存活率可達: 90%¹

Mr. Cheung Tat-ming, an NPC survivor:

The survival rate of early-stage NPC patients could be higher than 90%¹



了解更多
Learn More



網購平台
E-shop



(852) 5377 0823



(852) 3613 0533




take2health.net



Take2 Health

獨具慧眼迎商機 創新出版知趨勢



SINCE
1981

ELECTROLYZED WATER GENERATOR

NaOCl[®]clean[®]

NO.1 SYSTEM IN THE WORLD



ECO-FRIENDLY



NO CHEMICAL

STERINIZING · DEODORIZING · CLEANING at ONCE
USING **ONLY A SALT** WITHOUT **CHEMICALS**

BACTERIA, VIRUS 99.99%
EFFECTIVELY REMOVE **BIOFILM**



g-niib.com/M3CRC

G-Niib[®] M3CRC[™]

大腸健康 未照先知

話咁易做完

G-Niib[®] M3CRC[™]

倚測大腸癌
靈敏度¹ 94%



榮獲
2022年日內瓦
國際發明展
銀獎



本地大學研發³
全球首創¹
非入侵性

專利偵測大腸癌惡菌⁴
測出大腸癌
小瘻肉及其復發^{1,2}

只需
糞便樣本

大腸檢測 方便快捷

本地大學腸道微生物群研究中心

☎ 2903 0700

¹ A novel, non-invasive, non-invasive method for the non-invasive diagnosis of colorectal adenoma and cancer. World J Gastroenterol 2017; 21(10): 2493-2500. doi:10.3745/wjg.v21.i10.2493

² Pathology. Yu J et al. Fecal Bacterial Marker for Colorectal Cancer. United States: US20200102179B1. Boston: EP20201046; Harvard Chan: CH2177920; Hong Kong: HK202002; Taiwan: TW202000026.

³ Research Paper: G-Niib M3CRC. Available at: www.g-niib.com



Your trusted partner for clinical research services

Thailand's Leading CRO



One-stop clinical research services
that meets international standards

To learn more about the benefits of partnering with us,



www.clinixir.com



+66 2 163 6430



About us

AP Infosense was established in 2016 at Hong Kong Science Park and is a member of AP Group (<https://apimetrology.com/>). We are committed to deliver advanced Sensing Technologies ready for IoT platform especially customer-inspired technologies in the areas of Vision, Precision Engineering, Sensors, Robotics, Medical Device and Advanced Fabrication.

As an international perspective of API China, AP Infosense Limited (Hong Kong) has been granted support from the Hong Kong Government's Innovation and Technology Fund to innovate high-end sensing technologies ready for commercialization.



3D Vision



Precision Engineering



Sensors



Robotics



Medical Devices




Advanced Fabrication

Product overview

API MEDCAL 健康監測手掌感溫儀

A temperature sensing device for high accuracy (calibrated to ± 0.2 °C). API MEDCAL combines with apiVision, API's proprietary software for real time monitoring and data collecting. It's ideal for direct thermal inspection for biological features like palm, finger, and foot.

The interactive temperature zones display accurate temperature data to show rise and fall of real time temperate recording biological features to indicate health condition.



High 2mm pixel density



Flexible to fit different curvatures



Proprietary software for data recording




High temperature accuracy ± 0.2 °C


API WHITE LIGHT INTERFEROMETER 白光干涉儀

An advance 3D imaging system with sub-micron accuracy, measuring 3D profile image in seconds with high accuracy. Suitable for advanced manufacturing process such as Semi-Conductor, PCB, and metal roughness measurement which demands for high resolution 3D imaging system for quality control.

Unlike traditional interferometer and optical profiler that can only measure surface profile. API's WLI can be used for analyzing translucence multi-layer samples, as it utilizes white light with low coherence light that is harmless to biological samples including stem cells for emerging needs of biological studies and researches.



A 3D profile of a HKD\$10 note



A 3D profile of a cell



Non-contact 3D profiling




White LED light source



High resolution



Fast scanning



115

No. C03

Contact



Unit 317, 8W, Hong Kong Science Park



info@apinfosense.com



www.apinfosense.com



(852) 3703 9591





Advanced Therapy Products GMP CENTRE



FIND OUT MORE



FOR ENQUIRES



atpgmp@hkib.org.hk
tcm@hkib.org.hk




香港生物科技研究院有限公司

The Hong Kong Institute of Biotechnology Limited



MGI Core Proprietary DNBSEQ™ Technology



High Accuracy

Precision*99.4%
Sensitivity*98.8%

Low Duplicates

<3%

Low Index Hopping

0.0001%-0.0004%

*Using PRC-Free method for preparation



CHELATED PLATINUM
SOLUTION 螯合鉑金液

BioHK2022's
Sterilisation
Sponsor

Booth
B01-B02

UT 宇天新技術有限公司
UT Innovation Limited

CMA
TESTING

ESTC

SGS



OECD

Patented
Air-Sterilization
Technology

Chelated
Platinum



Kills
99.99%
of germs



No harmful
chemicals



One and
only brand
to achieve
drinking
water
standards



Instantaneously
releases
negative
ions without
side-effect
(ozone)



Exclusive distributor:

A Plus Healthcare Development LTD.

Technology from:

UT Innovation LTD.

www.ut-innovation.com

[chelated solution](#)

online shop



一次過了解您的肺部健康狀況、患上脂肪肝的風險和腎臟功能評估

gense

All-in-one device assessing lung function, fatty liver condition and kidney function

- ✓ 容易使用
Easy-to-use
- ✓ 安全無輻射
Safe and non-invasive
- ✓ 無需專業醫學培訓
Does not require medical training
- ✓ 追蹤慢性疾病情況
Longitudinal monitoring of chronic diseases

mediscan
科研團隊研發測試裝置



 肺功能測試
Lung Function Test

 脂肪肝檢查
Fatty Liver Test

 慢性腎病監察
Chronic Kidney Disease Monitoring



gense mediscan – 便攜式醫學成像裝置針對家居、護老院及診所等場地進行預防性健康篩查和慢性疾病監測

Our portable medical imaging device targets preventive screening and chronic disease monitoring at home, elderly homes, clinics and more



mediscan 電極帶
獨有無痛無輻射測試帶

 可作家居健康監測
無需前往醫院或診所
Home-based health monitoring

 適用於社區中心
進行篩查測試
Screening Services at community centres

 適用於護老院
頻繁健康篩查和監測
Health screening & Longitudinal monitoring at elderly homes

 降低治療
慢性病成本
Reducing costs of treating chronic diseases

 基層醫療
最佳化
Optimizing primary care

獎項
Awards

Forbes Asia
100
TO WATCH
福布斯

 **JUMPSTARTER**
JUMP START YOUR DREAMS

Grand Award
大獎
HONG KONG
ICT AWARDS
2021 香港資訊及
通訊科技獎

Gold Award
金獎
HONG KONG
ICT AWARDS
2021 香港資訊及
通訊科技獎

Gent

 **START-UP EXPRESS**
創業快線

 Asia Social
Innovation Award
亞洲社會創新獎

DREAM CATCHERS

 hello
tomorrow
ASIA PACIFIC

 **SME IECG**

Vision

To focus on the frontiers of original ocean science research and to solve the key scientific & technological issues of sustainable ecological development and sustainable utilization of marine resources in the greater bay area. . . .

Mission

To be the key unit of "Provincial Laboratory", to be a world-class marine research centre; and to lead the overseas major scientific research projects.

Contact Us

Address

Hong Kong Branch of the Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)
Room 3641 - 3649, 3/F, Lifts 31-32
The Hong Kong University of Science and Technology
Clear Water Bay, Kowloon, Hong Kong

General Enquiries

Phone: (852) 3469 2384
Fax: (852) 2495 7851
Email: hkb@ust.hk

Visit Our Website



INDICAID™

COVID or Flu?

Don't let the
virus fool
you.



Single Test. Triple Relief.

INDICAID™
COVID-19/FLU A&B Rapid Antigen Test

New!




3-in-1 Rapid Test
(SARS-Cov-2, Influenza A&B)
Accurate results for your
timely treatment



Result in 15 minutes
Rapid differentiation
despite common
symptoms



Easy Self-Swab
Painless shallow nasal swab



Accuracy 99%*
Developed in
Hong Kong

*Visit official website
for more details

PHASESCIENTIFIC

PHASE Scientific International Limited
1/F, Building 22E, Phase 3,
Hong Kong Science Park, Shatin,
New Territories, Hong Kong

+852 3700 8888
cs@indicaid.com
www.indicaid.com



ART-Quant™



Lab on the Phone

A sustainable solution to manage COVID-19 effectively

Quantification Is Disruptive



H.Pylori



Colorectal Cancer



Chest Pain



COVID-19



Antibody



Pregnancy

Lateral Flow Devices

Diagnostics

Selected are serological diagnostic examples*

Precision diagnostics is the key step to unlocking the full potential of personalised treatment

New Market

Precision Medicine Personalised Treatment

Adoption Barrier

Our vision is to harness the power of artificial intelligence and big data to accelerate the applications of precision diagnostics in personalised medicine- to quantify what your health precisely needs

For more inquiries,
please contact: chris.pang@haikanglife.com
Strictly confidential. All rights reserved

www.art-quant.com

Supporting Organizations

Organizers



Co-Organizers



Diamond Sponsors



Gold Sponsors





Silver Sponsors



Special Supporting Organizations



Supporting Organizations



Global Partners



Media Partners



Technology Support Consultant



Acknowledgement



Official Carrier



*Thank
you!*

ACKNOWLEDGEMENT

A Plus Healthcare Development Limited
Mattey Supply Company Limited
Philip K.H. Wong Foundation
Sanwa Biotech Limited
Sunlight Eco-tech Limited

Mr.Amos Wu

SPECIAL ACKNOWLEDGEMENT

Brand Hong Kong
HKSAR's 25th Anniversary

BIOHK2023

Hong Kong International Biotechnology Convention

HONG KONG CONVENTION & EXHIBITION CENTRE

13-16
SEPTEMBER
2023

Hong Kong International Biotechnology Convention BIOHK2023

香港國際生物科技展

BIOHK PROGRAM

2023

EXHIBITION
CONFERENCE
ONLINE MATCHING
BIO INVEST
BIO CAREER

BIOTECHGAZINE · 生物科技誌

BIOTECHGAZINE · 生物科技誌

SEE
YOU
AGAIN
IN

13 - 16
SEPTEMBER

2023

Address 地址 :

Units 601-605, 6/F, Biotech Centre One,
9 Science Park West Avenue,
Hong Kong Science Park,
N.T., Hong Kong
香港新界香港科學園科技大道西9號
生物科技中心一座601-605室

Email 電郵 : info@biotechgazine.com

Telephone 電話 : (+852) 2799 7688